CLINICAL TRIAL PROTOCOL

Protocol title: A 30-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Alone or in Combination with Sulfonylurea

Protocol number: EFC15337
Amendment number: Original protocol
Compound number (Trademark/INN): SAR439977/efpeglenatide
Short title: Efficacy and Safety of Efpeglenatide Versus Placebo in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Alone or in Combination with Sulfonylurea (AMPLITUDE-S)

Sponsor name: 
Legal registered address: 

Regulatory agency identifying number(s):

EudraCT number: Not applicable
IND number: 112780
UTN number: U1111-1205-1291

Approval Date: 20 June 2018 Total number of pages: 90

Any and all information presented in this document shall be treated as confidential and shall remain the exclusive property of Sanofi (or any of its affiliated companies). The use of such confidential information must be restricted to the recipient for the agreed purpose and must not be disclosed, published or otherwise communicated to any unauthorized persons, for any reason, in any form whatsoever without the prior written consent of Sanofi (or the concerned affiliated company); ‘affiliated company’ means any corporation, partnership or other entity which at the date of communication or afterwards (i) controls directly or indirectly Sanofi, (ii) is directly or indirectly controlled by Sanofi, with ‘control’ meaning direct or indirect ownership of more than 50% of the capital stock or the voting rights in such corporation, partnership or other entity

According to template: Version Sanofi dated 12-SEP-2017 based on TransCelerate CPT version 4
Sponsor signatory:

Please refer to the last page of this document for electronic signatures including date and time.

Monitoring Team's Representative
Name and Contact Information:
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>TABLE OF CONTENTS</td>
<td>3</td>
</tr>
<tr>
<td>LIST OF TABLES</td>
<td>7</td>
</tr>
<tr>
<td>LIST OF FIGURES</td>
<td>7</td>
</tr>
<tr>
<td><strong>1 PROTOCOL SUMMARY</strong></td>
<td>8</td>
</tr>
<tr>
<td>1.1 SYNOPSIS</td>
<td>8</td>
</tr>
<tr>
<td>1.2 SCHEMA</td>
<td>13</td>
</tr>
<tr>
<td>1.3 SCHEDULE OF ACTIVITIES (SOA)</td>
<td>14</td>
</tr>
<tr>
<td><strong>2 INTRODUCTION</strong></td>
<td>19</td>
</tr>
<tr>
<td>2.1 STUDY RATIONALE</td>
<td>19</td>
</tr>
<tr>
<td>2.2 BACKGROUND</td>
<td>19</td>
</tr>
<tr>
<td>2.3 BENEFIT/RISK ASSESSMENT</td>
<td>20</td>
</tr>
<tr>
<td><strong>3 OBJECTIVES AND ENDPOINTS</strong></td>
<td>22</td>
</tr>
<tr>
<td>3.1 APPROPRIATENESS OF MEASUREMENTS</td>
<td>23</td>
</tr>
<tr>
<td><strong>4 STUDY DESIGN</strong></td>
<td>25</td>
</tr>
<tr>
<td>4.1 OVERALL DESIGN</td>
<td>25</td>
</tr>
<tr>
<td>4.2 SCIENTIFIC RATIONALE FOR STUDY DESIGN</td>
<td>25</td>
</tr>
<tr>
<td>4.3 JUSTIFICATION FOR DOSE</td>
<td>26</td>
</tr>
<tr>
<td>4.4 END OF STUDY DEFINITION</td>
<td>26</td>
</tr>
<tr>
<td><strong>5 STUDY POPULATION</strong></td>
<td>27</td>
</tr>
<tr>
<td>5.1 INCLUSION CRITERIA</td>
<td>27</td>
</tr>
<tr>
<td>5.2 EXCLUSION CRITERIA</td>
<td>28</td>
</tr>
<tr>
<td>5.3 LIFESTYLE CONSIDERATIONS</td>
<td>30</td>
</tr>
<tr>
<td>5.3.1 Meals and dietary restrictions</td>
<td>30</td>
</tr>
<tr>
<td>5.4 SCREEN FAILURES</td>
<td>31</td>
</tr>
<tr>
<td><strong>6 STUDY INTERVENTION</strong></td>
<td>32</td>
</tr>
</tbody>
</table>
6.1 STUDY INTERVENTION(S) ADMINISTERED ................................................................. 32
6.1.1 INVESTIGATIONAL MEDICINAL PRODUCTS ....................................................... 33
6.1.2 NONINVESTIGATIONAL MEDICINAL PRODUCT .................................................. 34
6.2 PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY .......................................... 37
6.3 MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING ......................... 38
6.3.1 Methods of blinding ............................................................................................... 38
6.3.2 Randomization code breaking during the study ....................................................... 39
6.4 STUDY INTERVENTION COMPLIANCE .................................................................. 39
6.4.1 Return and/or destruction of treatments ................................................................. 40
6.5 CONCOMITANT THERAPY ...................................................................................... 40
6.6 DOSE MODIFICATION ............................................................................................. 41
6.7 INTERVENTION AFTER THE END OF THE STUDY .................................................. 41

7 DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL ................................................................. 42
7.1 DISCONTINUATION OF STUDY INTERVENTION ...................................................... 42
7.1.1 Permanent discontinuation ................................................................................... 42
7.1.2 Temporary discontinuation .................................................................................... 43
7.1.3 Rechallenge .......................................................................................................... 44
7.2 PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY .................... 44
7.3 LOST TO FOLLOW UP ............................................................................................... 45

8 STUDY ASSESSMENTS AND PROCEDURES ................................................................... 46
8.1 EFFICACY ASSESSMENTS ...................................................................................... 46
8.1.1 Hemoglobin A1c .................................................................................................... 46
8.1.2 Fasting plasma glucose ......................................................................................... 46
8.1.3 Body weight ......................................................................................................... 46
8.1.4 7-point self-monitored plasma glucose profiles .................................................... 47
8.1.5 Use of rescue therapy ......................................................................................... 47
8.2 SAFETY ASSESSMENTS ......................................................................................... 48
8.2.1 Physical examinations ......................................................................................... 48
8.2.2 Vital signs ............................................................................................................ 48
8.2.3 Electrocardiograms ............................................................................................. 49
8.2.4 Clinical safety laboratory assessments ................................................................. 49
8.2.5 Hypoglycemia ..................................................................................................... 50
8.3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS
8.3.1 Time period and frequency for collecting AE and SAE information
8.3.2 Method of detecting AEs and SAEs
8.3.3 Follow-up of AEs and SAEs
8.3.4 Regulatory reporting requirements for SAEs
8.3.5 Pregnancy
8.3.6 Cardiovascular and death events
8.3.7 Disease-related events and/or disease-related outcomes not qualifying as AEs or SAEs
8.3.8 Guidelines for reporting product complaints/medical device incidents (including malfunctions)
8.4 TREATMENT OF OVERDOSE
8.5 PHARMACOKINETICS
8.6 PHARMACODYNAMICS
8.7 GENETICS
8.8 BIOMARKERS
8.8.1 Immunogenicity assessments
8.9 HEALTH ECONOMICS
9 STATISTICAL CONSIDERATIONS
9.1 STATISTICAL HYPOTHESES
9.2 SAMPLE SIZE DETERMINATION
9.3 POPULATIONS FOR ANALYSES
9.4 STATISTICAL ANALYSES
9.4.1 Efficacy analyses
9.4.2 Safety analyses
9.4.3 Other analyses
9.5 INTERIM ANALYSES
9.5.1 Data Monitoring Committee (DMC)
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1 APPENDIX 1: REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS
10.1.1 Regulatory and Ethical Considerations
10.1.2 Informed Consent Process
10.1.3 Data Protection
10.1.4 Committees Structure

10.1.5 Dissemination of Clinical Study Data

10.1.6 Data Quality Assurance

10.1.7 Source documents

10.1.8 Study and Site Closure

10.1.9 Publication Policy

10.2 APPENDIX 2: CLINICAL LABORATORY TESTS

10.3 APPENDIX 3: ADVERSE EVENTS: DEFINITIONS AND PROCEDURES FOR RECORDING, EVALUATING, FOLLOW-UP, AND REPORTING

10.4 APPENDIX 4: CONTRACEPTIVE GUIDANCE AND COLLECTION OF PREGNANCY INFORMATION

10.5 APPENDIX 5: LIVER AND OTHER SAFETY: SUGGESTED ACTIONS AND FOLLOW-UP ASSESSMENTS

10.5.1 Laboratory abnormalities

10.5.2 Monitoring of participants with increased lipase and/or amylase >2 ULN

10.5.3 Management of participants with increased calcitonin values

10.5.4 Gastrointestinal events in relation to acute renal failure

10.6 APPENDIX 6: MEDICAL DEVICE INCIDENTS: DEFINITION AND PROCEDURES FOR RECORDING, EVALUATING, FOLLOW-UP, AND REPORTING

10.7 APPENDIX 7: COUNTRY-SPECIFIC REQUIREMENTS

10.8 APPENDIX 8: HYPOGLYCEMIA CLASSIFICATION

10.9 APPENDIX 9: ABBREVIATIONS

11 REFERENCES
LIST OF TABLES

Table 1 - Objectives and endpoints...............................................................................................................22
Table 2 - Overview of study interventions administered ...............................................................................32
Table 3 - Rescue criteria ................................................................................................................................35
Table 4 - Populations for analyses ................................................................................................................58
Table 5 - Efficacy analyses ...........................................................................................................................58
Table 6 - Safety analyses..............................................................................................................................63
Table 7 - Other analyses ..................................................................................................................................64
Table 8 - Protocol-required safety laboratory assessments ...........................................................................70
Table 9 - Highly effective contraceptive methods .........................................................................................77

LIST OF FIGURES

Figure 1 - Graphical study design .................................................................................................................13
Figure 2 - Hypoglycemia classification .........................................................................................................87
1 PROTOCOL SUMMARY

1.1 SYNOPSIS

Protocol title: A 30-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Alone or in Combination with Sulfonylurea

Short title: Efficacy and Safety of Efpeglenatide Versus Placebo in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Alone or in Combination with Sulfonylurea (AMPLITUDE-S)

Rationale:

This study is designed to demonstrate the efficacy and safety of efpeglenatide in participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control with metformin alone or in combination with sulfonylurea (SU). Efpeglenatide will be compared to placebo.

Objectives and endpoints

<table>
<thead>
<tr>
<th>Objectives</th>
<th>Endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary</strong></td>
<td>Change from baseline to Week 30 in HbA1c</td>
</tr>
<tr>
<td>To demonstrate the superiority of once weekly injection of efpeglenatide 2, 4, or 6 mg in comparison to placebo in HbA1c change from baseline to Week 30 in participants with T2DM inadequately controlled with metformin alone or in combination with SU</td>
<td></td>
</tr>
<tr>
<td><strong>Secondary</strong></td>
<td>Number of participants with HbA1c &lt;7.0% at Week 30</td>
</tr>
<tr>
<td>To demonstrate the superiority of once weekly injection of efpeglenatide 2, 4, and 6 mg in comparison to placebo on glycemic control</td>
<td>Change from baseline to Week 30 FPG</td>
</tr>
<tr>
<td>To demonstrate the superiority of once weekly injection of efpeglenatide 2, 4, and 6 mg in comparison to placebo on body weight</td>
<td>Change from baseline to Week 30 in body weight</td>
</tr>
<tr>
<td>To evaluate the safety of once weekly injection of efpeglenatide 2, 4, and 6 mg</td>
<td>Number of participants with at least 1 hypoglycemic event during treatment period</td>
</tr>
<tr>
<td></td>
<td>Number of hypoglycemic events per participant-year during treatment period</td>
</tr>
<tr>
<td></td>
<td>Number of participants with AEs (see Section 8.3)</td>
</tr>
</tbody>
</table>

AE: Adverse event; FPG: fasting plasma glucose; HbA1c: hemoglobin A1c; SU: sulfonylurea; T2DM: type 2 diabetes mellitus.
Overall design:

This study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 4-arm, parallel group study in participants with T2DM inadequately controlled with metformin alone or in combination with SU.

The randomization (1:1:1:1) to efpeglenatide 2 mg, efpeglenatide 4 mg, efpeglenatide 6 mg, or placebo will be stratified by screening hemoglobin A1c (HbA1c) (<8%, ≥8%) and SU use at screening (Yes/No).

An independent Data Monitoring Committee (DMC) will review clinical study safety data and an Independent Clinical Endpoint Committee (CEC) will review, assess, and/or adjudicate all events of death, selected cardiovascular adverse events (AEs), pancreatic events, and other selected AEs (see Appendix 1 [Section 10.1] for further details of study committees).

Number of participants:

Sufficient participants will be screened to achieve 640 participants randomized to study treatment (160 participants per treatment group). It is expected that approximately 400 participants to be enrolled from China and approximately 240 participants from the US, with approximately 50% of participants being on metformin alone and approximately 50% on metformin + SU. All randomized participants will be included in the population analyzed for efficacy endpoints. Section 9.2 gives details of the sample size determination.

Intervention groups and duration:

The study comprises 3 periods as follows:

- An up to 3-week screening period (with a minimum of 10 days)
- A 30-week double-blind, placebo-controlled treatment period for efficacy and safety assessments
- A 6-week posttreatment follow-up period to collect safety information after last dose of IMP

The maximum study duration per participant will be 39 weeks.

Study interventions

Investigational medicinal product

Efpeglenatide/Matching placebo

- Formulation: 500 µL of a sterile, non-pyrogenic, clear, colorless solution in a 1 mL disposable prefilled syringe (PFS)
- Route of administration: subcutaneous (SC)
- Dose regimen: SC injection once weekly on the same week day (eg, each Monday) at any time of the day
The dose will be titrated as shown in the table below. From Week 4 (Visit 5) through the rest of the double-blind treatment period, participants will remain on the randomized investigational medicinal product (IMP) until the end of treatment (EOT) at Week 30 (Visit 11).

### Investigational medicinal product dose schedule

<table>
<thead>
<tr>
<th>Dose 1</th>
<th>Dose 2</th>
<th>Dose 3</th>
<th>Dose 4</th>
<th>Dose 5 onward</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 1</td>
<td>Week 1</td>
<td>Week 2</td>
<td>Week 3</td>
<td>Week 4</td>
</tr>
<tr>
<td>Visit 3</td>
<td>Visit 4</td>
<td>Visit 5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efpeglenatide 2 mg</td>
<td>2 mg</td>
<td>2 mg</td>
<td>2 mg</td>
<td>2 mg</td>
</tr>
<tr>
<td>Efpeglenatide 4 mg</td>
<td>2 mg</td>
<td>2 mg</td>
<td>4 mg</td>
<td>4 mg</td>
</tr>
<tr>
<td>Efpeglenatide 6 mg</td>
<td>2 mg</td>
<td>2 mg</td>
<td>4 mg</td>
<td>4 mg</td>
</tr>
<tr>
<td>Placebo</td>
<td>Placebo</td>
<td>Placebo</td>
<td>Placebo</td>
<td>Placebo</td>
</tr>
</tbody>
</table>

### Noninvestigational medicinal products

**Metformin and sulfonylurea**

- Route(s) of administration: Oral
- Dose regimen: Administered as per Investigator and in accordance with local labeling. Metformin, if taken as the only oral antidiabetic (OAD), should be at a dose of \( \geq 1500 \text{ mg/day} \) (or maximum tolerated dose, or as per country regulation if less). Sulfonylurea, if taken, should be at least half of maximum recommended dose according to national label. Dose(s) should be kept stable throughout the study unless dose reduction is needed for safety reasons.

**Rescue therapy**

- Route(s) of administration: Oral, injectable
- Dose regimen: Open-label rescue medication(s) to treat hyperglycemia will be prescribed at the discretion of the Investigator and in accordance with local standard of care and prescribing practice. With the exception of other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, any approved medication(s) can be prescribed to treat the hyperglycemia. If a participant requires glycemic rescue, the IMP received during the randomized, double-blind treatment period should be continued (unless the Investigator considers a change necessary for safety reasons) and must remain blinded until the end of the study. Refer to Section 6.1.2.2 for full details of rescue therapy.
Statistical considerations:

- **Primary analysis:**

  The primary efficacy endpoint (change from baseline to Week 30 in HbA1c) will be analyzed using HbA1c values measured at baseline and Week 30 (observed or imputed), regardless of treatment discontinuation or initiation of rescue therapy.

  The primary analysis method for the primary efficacy endpoint will be an analysis of covariance (ANCOVA) model with missing values imputed by multiple imputation (MI) analysis methods in 2 parts as follows:

  1. Missing endpoint data for participants who prematurely discontinue the IMP before the endpoint visit will be imputed using a model estimated from participants in the same treatment arm who prematurely discontinue the IMP before the endpoint visit but have the measurements for the endpoint (retrieved dropouts). Considering that the number of participants in each treatment arm who discontinue the IMP but have the measurement for the endpoint is expected to be small, we propose to use a simple imputation model, where only the baseline measurements are included as the predictors. Each treatment group will have their own imputation model. Missing data will be imputed using the regression method.

  2. Missing endpoint data in all participants, including those in the efpeglenatide groups, who stay on the IMP until the endpoint visit, will be imputed separately, using a model estimated from participants in the placebo group who stay on the IMP until the endpoint visit and have the endpoint data available. The imputation model will include the randomization strata (screening HbA1c [<8%, ≥8%], SU use at screening [Yes/No]), and baseline HbA1c value. Missing data will be imputed using the regression method.

In this analysis, missing endpoint values will be imputed 10 000 times to generate 10 000 data sets with complete data. Each of the completed datasets after the imputation will be analyzed by the ANCOVA model with the treatment groups (efpeglenatide 2, 4, or 6 mg, placebo), randomization stratum of screening HbA1c (<8%, ≥8%), randomization stratum of screening SU (Yes/No) and country (US; China) as fixed effects, and baseline HbA1c value as a covariate. The baseline value is defined as the last available value prior to the first dose administration of IMP or the last available value on or before the date of randomization if not treated with the double-blind IMP.

The results from the 10 000 analyses will be combined using Rubin’s formula to provide the adjusted mean change in HbA1c from baseline to Week 30 (regardless of IMP discontinuation or initiation of rescue therapy) for each treatment group, as well as the difference between each efpeglenatide dose and placebo and the 95% confidence interval (CI) for the difference.

As noted, the number of retrieved dropouts is expected to be small, and there may not be sufficient data to support the imputation approach in item 1 described above. If there are fewer than 5 participants, in any treatment arm, who prematurely discontinue the IMP before the Week 30 visit but have the HbA1c measurements for the endpoint, a back-up imputation method for the primary efficacy analysis will be used. In particular, missing endpoint data for all participants in both efpeglenatide and placebo groups, regardless of staying on the IMP or not,
will be imputed using a model estimated from participants in the placebo group with endpoint data, where randomization strata and baseline HbA1c values are included as the predictors. Missing data will be imputed using the regression method.

A hierarchical procedure will be performed to adjust for the multiplicity of comparison. First, the highest dose of efpeglenatide (6 mg) will be compared to placebo. If superiority is demonstrated for the 6 mg dose of efpeglenatide, the superiority of the 4 mg dose of efpeglenatide versus placebo will be tested. If superiority is also demonstrated for the 4 mg dose of efpeglenatide, the lowest dose (2 mg) will be tested for superiority over placebo. When superiority is not obtained in a step, the sequential testing procedure will be stopped.

Summary statistics (for screening value, baseline value, observed values, and observed changes from baseline) at scheduled visits will be provided for each treatment group over the double-blind treatment period. The summary will include the number of observations, mean, standard deviation (SD), standard error (SE), minimum, median, and maximum. Graphical presentations will also be used to examine trends over time using mean values (±SE) and mean changes from baseline (±SE) at each of the scheduled visits (using observed cases[OC]).

- **Analysis of secondary and other efficacy endpoints:**

Continuous secondary efficacy endpoints will be analyzed using the same ANCOVA model with missing values imputed by MI method as the method used for the primary efficacy endpoint analysis. Differences between treatment groups and CIs will be estimated by this method. Categorical efficacy endpoints will be analyzed by the Cochran-Mantel-Haenszel method stratified by the randomization strata. For the HbA1c <7.0% analysis, participants with missing HbA1c data at Week 30 will be considered non-responders in the intent-to-treat (ITT) population.

Comparisons of time-to-event endpoints between treatment groups will be performed using the Cox proportional hazards regression model with the treatment groups (efpeglenatide 2, 4, or 6 mg, placebo), randomization stratum of screening HbA1c (<8%, ≥8%), randomization stratum of screening SU use (Yes/No), and country (US, China) as the factors.

1. **Data Monitoring Committee: Yes**

See Appendix 1 (Section 10.1) for details.
1.2 SCHEMA

Figure 1 - Graphical study design

1:1:1:1 randomization, stratified by HbA1c (<8.0% and ≥8.0%) and SU use (Yes/No) at screening.
Visit schedule: From Visit 1 (Week -3) to Visit 12 (Week 30/EOT + 6 weeks)
EOS: end of study; EOT: end of treatment; R: Randomization.
### 1.3 SCHEDULE OF ACTIVITIES (SOA)

<table>
<thead>
<tr>
<th>Visit</th>
<th>Screening</th>
<th>Double-blind placebo-controlled Treatment period</th>
<th>Post-treatment Follow-up</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1  2  3  4  5  6  7  8  9  10  11  12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>R</td>
<td>EOT</td>
<td>EOS</td>
<td></td>
</tr>
<tr>
<td>Week</td>
<td>-3 -1 0  2  4  6  8  12  18  24  30*</td>
<td></td>
<td>Last IMP + 6 weeks</td>
<td></td>
</tr>
<tr>
<td>Acceptable range (days)</td>
<td>-10 to - 21  -7 (±3)</td>
<td>1  14 (±3)  28 (±3)  42 (±3)  56 (±3)  84 (±3)  126 (±3)  168 (±3)  210 (±3)  259 (±7)</td>
<td>V2 can be done as soon as the screening eligibility is confirmed. V3 can be done 4 to 10 days after V2. V3 should be done at least 10 days after V1 (to allow IMP to be sent to the site) and no later than 21 days after V1.</td>
<td></td>
</tr>
<tr>
<td>Injection of weekly dose on the day of visit</td>
<td>X X X</td>
<td>X X X</td>
<td>Participant will self-administer the injection only after blood samples (if any) have been drawn at the respective visit.</td>
<td></td>
</tr>
<tr>
<td>Injection of weekly dose may be on a different day than visit</td>
<td>X X X</td>
<td>X X X</td>
<td>See Table 2 for details of dosing windows</td>
<td></td>
</tr>
<tr>
<td>Informed consent</td>
<td>X</td>
<td></td>
<td>Informed consent taken prior to any study-related procedures being performed.</td>
<td></td>
</tr>
<tr>
<td>Inclusion and exclusion criteria</td>
<td>X X X</td>
<td></td>
<td>Check eligibility before Visit 2 and before randomization</td>
<td></td>
</tr>
<tr>
<td>Demography, medical/surgical history</td>
<td>X</td>
<td></td>
<td>Includes diabetes complications, cardiovascular (CV) and allergy history, alcohol and smoking habits</td>
<td></td>
</tr>
<tr>
<td>Physical examination</td>
<td>X X X</td>
<td>X X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vital signs</td>
<td>X X X X X X X X X</td>
<td></td>
<td>Blood pressure (BP) and heart rate (HR) in sitting position after at least 5 minutes of rest</td>
<td></td>
</tr>
<tr>
<td>Height</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body weight</td>
<td>X X x X X X X X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12-lead ECG</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>IMP injection training at V2/retraining as needed</td>
<td>X X X X</td>
<td>X X X</td>
<td></td>
<td>See Section 6.1.1</td>
</tr>
<tr>
<td>Visit</td>
<td>Screening</td>
<td>Double-blind placebo-controlled Treatment period</td>
<td>Post-treatment Follow-up</td>
<td>Notes</td>
</tr>
<tr>
<td>---------</td>
<td>-----------</td>
<td>--------------------------------------------------</td>
<td>--------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>2</td>
<td>3 4 5 6 7 8 9 10 11 12</td>
<td></td>
</tr>
<tr>
<td></td>
<td>R</td>
<td></td>
<td>EOT EOS</td>
<td></td>
</tr>
<tr>
<td>Week</td>
<td>-3</td>
<td>-1</td>
<td>0 Baseline 2 4 6 8 12 18 24 30a</td>
<td>Last IMP + 6 weeks</td>
</tr>
<tr>
<td>Acceptable range (days)</td>
<td>-10 to -21</td>
<td>-7 (±3) 1 14 (±3) 28 (±3) 42 (±3) 56 (±3) 84 (±3) 128 (±3) 168 (±3) 210 (±3) 259 (±7)</td>
<td>V2 can be done as soon as the screening eligibility is confirmed V3 can be done 4 to 10 days after V2 V3 should be done at least 10 days after V1 (to allow IMP to be sent to the site) and no later than 21 days after V1</td>
<td></td>
</tr>
<tr>
<td>Review of injection sites</td>
<td>X X X X X X X X X</td>
<td>X X X X X X X X X X X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diary dispensation</td>
<td>X X X X X X X X X X</td>
<td>X X X X X X X X X X X X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diary review and collection</td>
<td>X X X X X X X X X X X</td>
<td>X X X X X X X X X X X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Review of SMPG and metformin and sulfonylurea doses</td>
<td>X X X X X X X X X X X</td>
<td>X X X X X X X X X X X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose meter dispensation and training</td>
<td>X</td>
<td></td>
<td>Will include training for hypoglycemia awareness and management</td>
<td></td>
</tr>
<tr>
<td>Diet and life style counselling</td>
<td>X X X X X X X X X X X X</td>
<td>X X X X X X X X X X X X</td>
<td>As per current practice, to be documented</td>
<td></td>
</tr>
<tr>
<td>IRT contact</td>
<td>X X X X X X X X X X X</td>
<td>X X X X X X X X X X</td>
<td>At V2, placebo training kit(s) will be allocated; self-injection will be done at site (see Section 6.1.1)</td>
<td></td>
</tr>
<tr>
<td>IMP dispensation</td>
<td>X X X X X X X X X X</td>
<td>X X X X X X X X X X X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IMP collection and accounting</td>
<td>X X X X X X X X X X X</td>
<td>X X X X X X X X X X X</td>
<td>Training kit will be collected and accounted at V2 (see Section 6.1.1)</td>
<td></td>
</tr>
<tr>
<td>Compliance</td>
<td>X X X X X X X X X X X</td>
<td>X X X X X X X X X X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efficacy:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HbA1c</td>
<td>X X X X X X X X X X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FPG</td>
<td>X X X X X X X X X X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-peptide (fasting)</td>
<td>X</td>
<td></td>
<td>For this visit, participants need to come in fasting conditions as described in Section 5.3.1 and Section 8.1.2</td>
<td></td>
</tr>
<tr>
<td>Visit</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>-------</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>R</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EOT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EOS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Screening**

<table>
<thead>
<tr>
<th>Acceptable range (days)</th>
<th>-10 to -21</th>
<th>-7 (±3)</th>
<th>1 (±3)</th>
<th>4 (±3)</th>
<th>6 (±3)</th>
<th>8 (±3)</th>
<th>12 (±3)</th>
<th>18 (±3)</th>
<th>24 (±3)</th>
<th>30&lt;sup&gt;a&lt;/sup&gt; (±6 weeks)</th>
</tr>
</thead>
</table>

**Notes**

- V2 can be done as soon as the screening eligibility is confirmed.
- V3 can be done 4 to 10 days after V2.
- V3 should be done at least 10 days after V1 (to allow IMP to be sent to the site) and no later than 21 days after V1.

**7-point SMPG profiles**

- Performed on at least 1 day in the week prior to visits indicated. See Section 8.1.4 for details.

**Fasting (before breakfast) SMPG**

- Daily within the first 8 weeks after randomization and at least 3 days in the other weeks, prior to visits indicated. See Section 8.1.2 for details.

**Safety:**

- Hematology
- Clinical chemistry
- Calcitonin
- Lipid profile
- Urinalysis
- Pregnancy test (for women of childbearing potential)
- Serum FSH and estradiol
- ADA sampling

**Notes**

- Serum pregnancy testing (β-HCG) at screening for women of childbearing potential (WOCBP Appendix 4, Section 10.4). Urine pregnancy testing subsequently (at on-site visits and monthly at home in between visits). If the urine test is positive, serum β-HCG should be tested for confirmation of the pregnancy.

- For women of non-childbearing potential. In case the definition of postmenopausal or premenopausal cannot be satisfied (see Appendix 4, Section 10.4).

- Participants positive for ADAs at the end of study, and who experienced severe injection site or hypersensitivity reaction at any time during the study, will be asked to provide sample for anti-efpeglenatide antibodies assessments 4 and 6 months after the EOT.
<table>
<thead>
<tr>
<th>Visit</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Week</td>
<td>-3</td>
<td>-1</td>
<td>0</td>
<td>2</td>
<td>4</td>
<td>6</td>
<td>8</td>
<td>12</td>
<td>18</td>
<td>24</td>
<td>30a</td>
<td></td>
</tr>
<tr>
<td>Acceptable range (days)</td>
<td>-10 to -21</td>
<td>-7 (±3)</td>
<td>1 (±3)</td>
<td>14 (±3)</td>
<td>28 (±3)</td>
<td>42 (±3)</td>
<td>56 (±3)</td>
<td>84 (±3)</td>
<td>126 (±3)</td>
<td>168 (±3)</td>
<td>210 (±3)</td>
<td>259 (±7)</td>
</tr>
</tbody>
</table>

**Notes**

- V2 can be done as soon as the screening eligibility is confirmed.
- V3 can be done 4 to 10 days after V2.
- V3 should be done at least 10 days after V1 (to allow IMP to be sent to the site) and no later than 21 days after V1.

**PK sampling**

- All participants will have 1 blood sample collected just before their weekly injection of the IMP (and at least 6 days after last dosing of the IMP) for the predose IMP serum concentration (C<sub>trough</sub>) at selected clinical visits.

- For a subset of participants, 1 additional postdose sample will be taken either 4 days (±1 day) after first IMP dose or 4 days (±1 day) after 4th dose or 4 days (±1 day) after 12th dose. A separate consent will be signed. See Section 8.5.2

**Rescue therapy assessment**

- Continuous assessment and recording during treatment period.

**Concomitant medication review**

**AE/SAE recording**

**Reporting hypoglycemia (symptoms, SMPG)**

- Continuous assessment and recording throughout the study.

Hypoglycemia eCRF page must be filled in for all SMPG ≤70 mg/dL (3.9 mmol/L) and/or in case of symptoms suggesting hypoglycemia (between V1 and V2 SMPGs measured with nonstudy glucometer can be used).

---

*a In case of premature permanent IMP discontinuation, the participant should have a visit as soon as possible after the last IMP administration with the assessments normally planned for EOT visit. Afterwards, the participants should continue in the study up to the scheduled date of study completion and be followed according to the study procedures as specified in the protocol. Every effort should be made to have the participants complete the Week 30 Visit’s assessments (primary and main secondary endpoints) as the minimum. For safety reasons, participants who wish to terminate participation in the study, should be assessed 6 weeks (±1 week) from the last IMP dose (at the minimum) using the procedure normally planned for the posttreatment follow-up visit at EOS. At the time corresponding to their Week 30 Visit, all attempts will be made to contact the participant to inquire about safety and/or vital status.*
2 INTRODUCTION

Efpeglenatide is a GLP-1 RA that is being developed for once weekly treatment of T2DM.

2.1 STUDY RATIONALE

The aim for the present trial is to compare efpeglenatide once-weekly versus placebo as addition to metformin alone or with SU, in a population of subjects with T2DM, in terms of glycaemic control, weight control, and other efficacy and safety parameters.

2.2 BACKGROUND

Although lifestyle changes, including diet, and exercise, are valuable components of diabetes treatment, the vast majority of people with T2DM require pharmacological therapy to control the disease. Metformin is recommended as the standard first-line therapy in the absence of any contraindications or tolerability issues, as per current guidance. In case of metformin failure or intolerance, a combination of metformin with 1 of the 6 available treatment options (SU, thiazolidinedione, DPP-4 inhibitor, sodium/glucose cotransporter 2 (SGLT2) inhibitor, GLP-1 RA, or basal insulin) can be considered as second-line choices (1).

In recent years, the GLP-1 RA class of pharmacotherapy for T2DM has evolved as an effective treatment option, from multiple daily through daily-to-weekly injection. GLP-1 is an endogenous enteroendocrine hormone secreted by L-cells of the distal intestine in response to oral nutrient ingestion. It has multiple physiologic effects that contribute to controlling hyperglycemia, such as enhancing insulin secretion from pancreatic β-cells in a glucose-dependent manner, suppressing glucagon secretion, and slowing gastric emptying. Due to their glucose-dependent mechanism of action, GLP-1 RAs are generally associated with a low risk of hypoglycemia.

Efpeglenatide (SAR439977), a GLP-1 RA, is a novel long-acting exendin-4 (exenatide) analogue that is being developed for the treatment of T2DM by once-weekly SC injection. In clinical Phase 2 studies, it has shown effects on body weight and may therefore provide potential for development for use in obesity.

In total, 7 clinical studies (two Phase 1 studies and five Phase 2 studies) including approximately 1000 participants (~720 exposed to efpeglenatide) have been completed. The Phase 2 studies have been conducted in participants with T2DM and in obese nondiabetic individuals. In participants with T2DM, weekly doses between 0.3 to 4 mg or monthly doses between 8 to 16 mg were used, whereas in nondiabetic obese participants, weekly doses of 4 to 6 mg and doses of 6 mg and 8 mg every other week were investigated. Overall, these studies have demonstrated that efpeglenatide improves glycemic control and reduces body weight, with an overall favorable safety and tolerability profile consistent with currently available GLP-1 RAs. Based on Phase 1 and 2 study data, 3 weekly efpeglenatide doses (2, 4, or 6 mg) have been selected for use in Phase 3 studies. These doses are expected to demonstrate efficacy in the target population while mitigating potential safety concerns and the incidence of AEs.
Details (nonclinical and clinical) about efpeglenatide can be found in the latest edition of the Investigator’s Brochure (IB, [2]).

2.3 BENEFIT/RISK ASSESSMENT

The nonclinical toxicological data and the safety data from clinical studies with efpeglenatide to date (with a cut-off date of 22 June 2017) suggest a safety profile consistent with the known AE profile of currently marketed GLP-1 RAs with the exception of potential liver toxicity. The following safety procedures are planned for the clinical study EFC15337:

- Gastrointestinal (GI) disorders such as nausea/vomiting and rarely pancreatitis are the most common AEs to the GLP-1 RAs class. Thus far, no case of pancreatitis has been identified with efpeglenatide. The trend over time for nausea and vomiting events appeared dose related, with an increase after the first injection, and generally decreasing thereafter within a period of approximately 2 to 4 weeks. It is anticipated that the planned, gradual dose escalation scheme employed in study EFC15337 will reduce intensity and frequency of GI events, mainly nausea and vomiting.

- Increase in heart rate is a known side effect of GLP-1 RA. In study EFC15337, periodic monitoring of vital signs including heart rate and blood pressure (BP) will be regularly performed.

- The GLP-1 RA class has a box warning related to risk of thyroid C-cell tumors in the US label, based on findings in rodents. As the relevance for humans is unclear, GLP-1 RAs are contraindicated in patients with a personal or family history of medullary thyroid cancer (MTC) or in patients with multiple endocrine neoplasia syndrome Type 2 (MEN-2). In study EFC15337, patients with history of MTC or MEN-2 or with elevated calcitonin levels (≥5.9 pmol/L [20 pg/mL]) at screening will not be randomized. Calcitonin will be monitored throughout the study and guidelines for follow-up are provided if this threshold will be reached after randomization.

- Diabetic retinopathy complications have been reported for one of GLP-1 RAs (as of 05 December 2017). No cases have been reported for efpeglenatide. Patients with a recent or planned retinal treatment for retinopathy or maculopathy will be excluded in the current study. Diabetic retinopathy complications will be monitored throughout the study.

- Additional safety monitoring in study EFC15337 includes the collection of AEs, antidrug antibodies (ADAs, immunogenicity, [3, 4]), as well as safety laboratory and 12-lead electrocardiogram (ECG).

- In 3 large Phase 2 clinical studies with efpeglenatide (HM EXC-203, HM-EXC-204, and HM-EXC-205), overall, a total of 12 out of 571 participants on efpeglenatide and 3 out of 183 participants on comparators had post-baseline alanine aminotransferase (ALT) elevation ≥3 × ULN; most had confounding factors (2). In this study, patients with elevated liver enzymes >3 × upper limit of normal (ULN) or total bilirubin >1.5 × ULN (except in cases of Gilbert’s syndrome) will be excluded from participation. Liver function tests will be done regularly throughout the study.
Efpeglenatide concentrations will also be sampled in study EFC15337. These sparse pharmacokinetic (PK) samples will be used for population PK (popPK) analyses to determine the PK characteristics of efpeglenatide in the target T2DM population.

The risks to the study participants will be minimized by careful participant selection according to appropriate inclusion and exclusion criteria based on existing nonclinical and clinical data. During the study, participants will be closely monitored at the regular visits, including physical examinations and laboratory tests to monitor the glucose-lowering effects and to early detect eventual adverse reactions. Suggested actions and follow-up measurements for laboratory abnormalities and other safety findings are provided in Appendix 5 (Section 10.5) of the protocol.

Placebo injections will not contribute to lower the plasma glucose but the participation in the study may increase participant motivation and result in an improvement of glycemic control. In any case, the close monitoring will detect early deterioration of glycemic control and allow initiation of “rescue therapy” as deemed necessary. The HbA1c and fasting plasma glucose (FPG) tests will be performed approximately every 3 to 4 months. Participants will be provided with a glucose meter and test strips to regularly self-measure their plasma glucose. Central laboratory alerts on FPG and HbA1c (from Week 12 and onwards), will be set up to ensure that glycemic parameters remain under predefined rescue thresholds.

More detailed information about the known and expected benefits and risks and reasonably expected adverse events of efpeglenatide may be found in the IB (2).
# 3 OBJECTIVES AND ENDPOINTS

Table 1 - Objectives and endpoints

<table>
<thead>
<tr>
<th>Objectives</th>
<th>Endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary</strong></td>
<td></td>
</tr>
<tr>
<td>To demonstrate the superiority of once weekly injection of efpeglenatide</td>
<td>Change from baseline to Week 30 in HbA1c</td>
</tr>
<tr>
<td>2, 4, or 6 mg in comparison to placebo in HbA1c change from baseline</td>
<td></td>
</tr>
<tr>
<td>to Week 30 in participants with T2DM inadequately controlled with</td>
<td></td>
</tr>
<tr>
<td>metformin alone or in combination with SU</td>
<td></td>
</tr>
<tr>
<td><strong>Secondary</strong></td>
<td></td>
</tr>
<tr>
<td>To demonstrate the superiority of once weekly injection of efpeglenatide</td>
<td>Number of participants with HbA1c &lt;7.0% at Week 30</td>
</tr>
<tr>
<td>2, 4, and 6 mg in comparison to placebo on glycemic control</td>
<td>Change from baseline to Week 30 FPG</td>
</tr>
<tr>
<td>To demonstrate the superiority of once weekly injection of efpeglenatide</td>
<td>Change from baseline to Week 30 in body weight</td>
</tr>
<tr>
<td>2, 4, and 6 mg in comparison to placebo on body weight</td>
<td></td>
</tr>
<tr>
<td>To evaluate the safety of once weekly injection of efpeglenatide 2, 4,</td>
<td>Number of participants with at least 1 hypoglycemic event during treatment</td>
</tr>
<tr>
<td>and 6 mg</td>
<td>event during treatment period</td>
</tr>
<tr>
<td></td>
<td>Number of hypoglycemic events per participant-year during treatment</td>
</tr>
<tr>
<td></td>
<td>period</td>
</tr>
<tr>
<td></td>
<td>Number of participants with AEs (see Section 8.3)</td>
</tr>
<tr>
<td><strong>Tertiary/exploratory</strong></td>
<td></td>
</tr>
<tr>
<td>To compare the effects of once weekly injection of efpeglenatide 2, 4,</td>
<td>7-point SMPG profile at baseline and Week 30</td>
</tr>
<tr>
<td>and 6 mg with placebo on glycemic control</td>
<td>Change from baseline to Week 30 in mean 24-hour SMPG (7-point profile)</td>
</tr>
<tr>
<td></td>
<td>Change from baseline to Week 30 in plasma glucose excursions (2-hours</td>
</tr>
<tr>
<td></td>
<td>PPG minus preprandial plasma glucose at breakfast, lunch, and dinner)</td>
</tr>
<tr>
<td></td>
<td>based on 7-point SMPG data</td>
</tr>
<tr>
<td></td>
<td>Number of participants with rescue therapy used until Week 30</td>
</tr>
<tr>
<td></td>
<td>Time to initiation of rescue therapy</td>
</tr>
<tr>
<td>To characterize the pharmacokinetics (PK) of efpeglenatide</td>
<td>Serum concentration ($C_{trough}$) of efpeglenatide at predose (Weeks 4,</td>
</tr>
<tr>
<td></td>
<td>12, 24, 30)</td>
</tr>
<tr>
<td></td>
<td>Serum concentration of efpeglenatide at postdose (either 4 days [±1 day]</td>
</tr>
<tr>
<td></td>
<td>after first IMP dose [Week 1], or 4 days [±1 day] after 4th dose [Week 4],</td>
</tr>
<tr>
<td></td>
<td>or 4 days [±1 day] after 12th dose [Week 12] in a subset of participants,</td>
</tr>
<tr>
<td></td>
<td>at least 10% of total: [N= approximately 16 per group])</td>
</tr>
</tbody>
</table>
### Objectives

To evaluate the immunogenicity of once weekly injection of efpeglenatide 2, 4, and 6 mg

### Endpoints

- Number of participants by ADA status at scheduled visits
- Number of participants with treatment-induced ADAs (among the participants ADA negative or missing at baseline) during the study period
- Number of participants with treatment-boostered ADAs (among the participants ADA positive at Baseline) during the study period
- ADA titer at scheduled visits
- Number of participants by ADA cross-reactivity to endogenous GLP-1 at scheduled visits
- Number of participants by ADA cross-reactivity to endogenous glucagon at scheduled visits
- Number of participants with ADAs directed against the polyethylene glycol (PEG) linker of efpeglenatide at scheduled visits

---


### 3.1 APPROPRIATENESS OF MEASUREMENTS

Efpeglenatide, added to metformin alone or to metformin and SU in participants with T2DM who have inadequate glycemic control on their previous antidiabetic therapy, is expected to lower HbA1c over 30 weeks of treatment (primary efficacy analysis).

The concentration of HbA1c reflects the glycemic history of the previous 120 days and is thus an index of mean glycemia, documenting glycemic control over the past 2 to 3 months. Hemoglobin A1c has also been shown to correlate with the development of long-term complications of diabetes, and reduction of HbA1c is known to reduce the risk of long-term microvascular complications. Therefore, HbA1c is considered an appropriate measure for assessing the efficacy of a novel treatment for Type 2 diabetes.

The problem of weight gain in T2DM is widely recognized. More than 80% of individuals with T2DM who are overweight, many at the time of diagnosis. Consequently, iatrogenic weight gain is not only unwelcome, but represents an important clinical issue that can become a barrier to the successful management of glycemic control. Therefore, in this study assessing change in body weight from baseline to Week 30 is a secondary endpoint.

Improvements in preprandial and postprandial plasma glucose (PPG) have been observed with efpeglenatide in previous studies. Therefore, assessment of both preprandial plasma glucose and PPG (by 7-point self-monitored plasma glucose [SMPG] profile) is relevant in this study. These 2 parameters are also considered by regulatory agencies to be supportive of efficacy of an antidiabetic agent.
The other efficacy and safety assessments in this study are standard, well-established measurements for a Phase 3 study evaluating the treatment of T2DM in adult participants.

The duration of study is considered to be sufficient for achieving stable conditions with IMP after reaching the targeted dose, for enabling an adequate assessment of time dependent changes in HbA1c, and to evaluate the safety profile during the treatment period.
4 STUDY DESIGN

4.1 OVERALL DESIGN

The current protocol EFC15337, is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of efpeglenatide addition in participants inadequately controlled with metformin alone or in combination with SU.

Eligible participants will be randomly assigned to 1 of 3 dose levels of efpeglenatide (2, 4, or 6 mg) or to placebo, to be administered SC once weekly. Randomization will be stratified by HbA1c at screening (<8%, ≥8%) and SU use at screening (Yes/No). Masked weekly dose escalation over the course of 4 weeks will be used to reach the assigned 4 and 6 mg efpeglenatide weekly doses. Escalation will start from 2 mg once weekly to the maximum of 4 or 6 mg once weekly, as assigned at randomization. Participants randomly assigned to the efpeglenatide 2-mg dose arm will also initiate dosing at 2-mg once weekly and remain on this dose for the treatment duration. In order to blind the treatments, both efpeglenatide and placebo will be provided in volume matched PFSs.

The study will be comprised of 3 periods as follows:

- An up to 3-week screening period (with a minimum of 10 days)
- A 30-week double-blind, placebo-controlled treatment period, for efficacy and safety assessments
- A 6-week posttreatment follow-up period to collect safety information after last dose of IMP (treatment completed or permanent IMP discontinuation)

The maximum study duration per participant will be 39 weeks.

4.2 SCIENTIFIC RATIONALE FOR STUDY DESIGN

This study is designed to demonstrate the efficacy and safety of efpeglenatide when used as added antidiabetic treatment in participants with T2DM who have inadequate glycemic control with metformin alone or in combination with SU. Efpeglenatide will be compared to placebo. Based on the study design, the protocol stipulates that participants can receive antidiabetic rescue therapy according to a predefined algorithm.

A placebo control will be used to allow for an unbiased assessment of treatment effects and safety data. Bias will be minimized by randomizing the participants to treatment groups, blinding the participants, the Investigators, and the Sponsor to the treatment allocations, and by adjudicating the selected AEs in a blinded fashion.
A parallel-group, randomized, placebo-controlled design was selected because trial participants are exposed to a single treatment and dose and assignment to that treatment is based solely on chance. This design is free of the limitations of competing designs such as crossover in which there may be a carryover of effect from the first to the second treatment. Although this carryover effect can be minimized with a washout period, it is possible that some longer-term effects may persist. While the sample size of the parallel group design is larger to account for more variability when participants cannot serve as their own control, the above-mentioned limitations of the crossover design have led the randomized controlled trial design to be the standard for therapeutic confirmatory trials for regulatory approval such as this trial.

4.3 JUSTIFICATION FOR DOSE

The selection of efpeglenatide 2, 4, and 6 mg once weekly doses is based on the results of early phase studies.

Efpeglenatide has shown increasing efficacy up to the highest dose tested. Both once-weekly 2 mg and 4 mg doses have shown clinically relevant efficacy in study HM-EXC-203. The achieved HbA1c reduction indicates that the dose-response plateau has not been reached with the 4 mg dose so most likely, higher efficacy of the 6 mg dose compared to the 4 mg dose can also be expected for glycemic control in diabetic patients. The once-weekly 6 mg dose tested in non-diabetic subjects in the Phase 2 study (HM-EXC-205) has shown higher efficacy in the decrease of body weight than the once-weekly 4 mg dose in this population.

Nausea and vomiting events appeared to be dose-related and the trend over time showed an increase in incidence after the first injection with a general decrease thereafter for all tested doses. Based on the observed general decrease of GI events incidence after the first week of treatment with efpeglenatide, dose increases to achieve the higher doses of 4 and 6 mg (in the corresponding arm) will be in 2 mg step intervals every 2 weeks in order to minimize the GI adverse effects. The escalation step of 2 mg is small enough to contribute to improvement of GI tolerability at dose increase. With this dose escalation schedule, the dose of 4 mg once-weekly will be achieved 2 weeks after the first dose of efpeglenatide and the maximal dose of 6 mg once-weekly will be achieved only 4 weeks after the first dose of efpeglenatide.

Please refer to the IB for more details (2).

4.4 END OF STUDY DEFINITION

The end of the study is defined as the date of the last visit of the last participant in the study (as scheduled per protocol or if trial is stopped prematurely based on the advice of the independent DMC or other unforeseen development).
5 STUDY POPULATION

Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, is not permitted.

5.1 INCLUSION CRITERIA

Participants are eligible to be included in the study only if all of the following criteria apply:

Age

I 01. Participant must be ≥18 years of age at the time of signing the informed consent

Type of participant and disease characteristics

I 02. Participants with T2DM

I 03. Diabetes diagnosed at least 1 year before screening

I 04. Participants on a background antidiabetic treatment for which all of the below apply:
    a) Participants on metformin alone or in combination with SU, for at least 3 months prior to screening
    b) Participants on stable dose of at least 1500 mg/day of metformin (if this is the only OAD), or individually tolerated maximum dose, or as per country regulation if less, for at least 3 months prior to screening
    c) Participants on at least half of maximum approved dose of SU (if taken) according to national label and at a stable dose for at least 3 months prior to screening

I 05. HbA1c between 7.0% and 10.0% (inclusive) measured by the central laboratory at screening

Informed Consent

I 06. Capable of giving signed informed consent as described in Appendix 1 (Section 10.1.2), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
5.2 EXCLUSION CRITERIA

Participants are excluded from the study if any of the following criteria apply:

Medical conditions

E 01. History of severe hypoglycemia requiring emergency room admission or hospitalization within 3 months prior to screening

E 02. Retinopathy or maculopathy with one of the following treatments, either recent (within 3 months prior to screening) or planned: intravitreal injections or laser or vitrectomy surgery

E 03. Clinically relevant history of GI disease associated with prolonged nausea and vomiting, including (but not limited to) gastroparesis, unstable and not controlled gastroesophageal reflux disease requiring medical treatment within 6 months prior to screening or history of surgery affecting gastric emptying

E 04. History of pancreatitis (unless pancreatitis was related to gallstones and cholecystectomy has been performed), pancreatitis during previous treatment with incretin therapies, chronic pancreatitis, pancreatectomy

E 05. Personal or family history of MTC or genetic conditions that predisposes to MTC (eg, multiple endocrine neoplasia syndromes)

E 06. Body weight change of ≥5 kg within the last 3 months prior to screening

E 07. Systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg at randomization

E 08. Severe renal disease as defined by estimated glomerular filtration rate (eGFR, by Modification of Diet in Renal Disease [MDRD]) of <30 mL/min/1.73 m²

E 09. Laboratory findings at the Screening Visit:

- ALT or aspartate aminotransferase (AST) >3 × ULN or total bilirubin >1.5 × ULN (except in case of documented Gilbert’s syndrome)
- Amylase and/or lipase: >3 × ULN
- Calcitonin ≥5.9 pmol/L (20 pg/mL)

E 10. Known presence of factors that interfere with the HbA1c measurement (eg, specific hemoglobin variants, hemolytic anemia) compromising the reliability of HbA1c assessment or medical conditions that affect interpretation of HbA1c results (eg, blood transfusion or severe blood loss in the last 3 months prior to randomization, any conditions that shortens erythrocyte survival)
E 11. Any clinically significant abnormality identified either in medical history or during screening evaluation (e.g., physical examination, laboratory tests, ECG, vital signs) or any AE during screening period, which, in the judgment of the Investigator, would preclude safe participation in the study or constrains efficacy assessment

Prior/concomitant therapy

E 12. Participants having received any antidiabetic drug other than metformin and SU within 3 months prior to screening

E 13. Participants having received any type of insulin for more than 30 consecutive days at any time (except for treatment of gestational diabetes)

E 14. Systemic glucocorticoid therapy (excluding topical, intra-articular, or ophthalmic application, nasal spray, or inhaled forms) for more than 10 consecutive days in the last 3 months prior to screening

E 15. Gastric surgery or other gastric procedures intended for weight loss within 2 years prior to screening, or planned during study period

Prior/concurrent clinical study experience

E 16. Participation in any previous clinical trial of efpeglenatide/HM11260C

E 17. Exposure to any investigational drugs in the last 4 weeks or 5 half-lives, whichever is longer, prior to screening

E 18. Concomitant enrollment in any other clinical study involving an investigational study treatment or any other type of medical research

Other exclusions

E 19. Any contraindication to use metformin and SU (if taken) as defined in the national product label(s)

E 20. Hypersensitivity to any of the study treatments, or components thereof, or to any GLP-1 RAs

E 21. History of drug or alcohol abuse within 6 months prior to the time of screening

E 22. Pregnant (confirmed by serum pregnancy test at screening) or breastfeeding women

E 23. Women of childbearing potential (WOCBP) not willing to use highly effective method(s) of birth control (Appendix 4 [Section 10.4]) or who are unwilling to be tested for pregnancy during the study period and for at least 5 weeks after the last dose of IMP
E 24. Participant is an employee of the Sponsor, or is the Investigator or any Subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.

E 25. Any country-related specific regulation that would prevent the participant from entering the study.

E 26. Individuals committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.

**Additional criteria at the end of the Screening Period**

E 27. Participants unwilling or unable to comply with study procedures as outlined in the protocol.

E 28. Participants who withdraw consent during the screening period (starting from signed ICF).

### 5.3 LIFESTYLE CONSIDERATIONS

#### 5.3.1 Meals and dietary restrictions

**Diet and exercise**

Lifestyle and diet therapy provided before the time of screening is to be continued during the study. Individualized dietary and lifestyle counseling will be given by a healthcare professional as per Schedule of Activities (SoA; Section 1.3) and should be consistent with international or local guidelines for participants with T2DM (for example, see 5).

**Fasting conditions**

- For Visits 3 (Day 1), 7 (Week 8), 8 (Week 12), and 11 (Week 30), participants need to come to the study center in a fasting condition after an overnight fast of no less than 8 hours that consisted of no food or liquid intake, other than water.

- Fasting (prebreakfast) SMPG must be performed per the SoA (Section 1.3).
5.4 SCREEN FAILURES

Screen failures are defined as participants who consent to participate in the clinical study but are not subsequently randomized (randomly assigned to study IMP). A minimal set of screen failure information is required to ensure transparent reporting of screen failure participants to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, and any serious adverse events (SAEs).

Individuals who do not meet the criteria for participation in this study (screen failure) may be rescreened once in cases where the original screen failure was due to reasons expected to change at rescreening (based upon the Investigator’s clinical judgment). A participant should not be randomly assigned more than once (ie, entering the randomized period twice).
6 STUDY INTERVENTION

Study intervention is defined as any investigational intervention(s), marketed product(s), placebo, or medical device(s) intended to be administered to a study participant according to the study protocol.

The IMP includes efpeglenatide in 3 doses (2, 4, and 6 mg) and placebo for SC injection during the 30 weeks of treatment.

Non-IMP (NIMP) treatment is defined as previous background antidiabetic treatment (metformin, SU) and the rescue medication(s) that will be used to treat hyperglycemia if a participant’s glycemic values reach the applicable rescue threshold as defined in Section 6.1.2.2. Except for GLP-1 RAs and DPP-4 inhibitors, any approved medication(s) can be prescribed at the Investigator’s discretion to treat the hyperglycemia. The regimen of the rescue medication(s) will be in accordance with local standard of care and prescribing practice.

6.1 STUDY INTERVENTION(S) ADMINISTERED

<table>
<thead>
<tr>
<th>Study intervention name</th>
<th>Efpeglenatide</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosage formulation</td>
<td>Sterile, non-pyrogenic, clear, colorless solution in a 1 mL disposable PFS in the formulation buffer (containing citric acid monohydrate, L-methionine, polysorbate 20, D-mannitol, sodium hydroxide and water for injection)</td>
<td>Sterile, non-pyrogenic, clear, colorless solution in a 1 mL disposable PFS in the formulation buffer (containing citric acid monohydrate, L-methionine, polysorbate 20, D-mannitol, sodium hydroxide and water for injection)</td>
</tr>
<tr>
<td>Unit dose strength(s)/Dosage level(s)</td>
<td>2/500 µL, 4/500 µL, and 6 mg/500 µL (for 4, 8, and 12 mg/mL concentrations, respectively)</td>
<td>NA</td>
</tr>
<tr>
<td>Route of administration</td>
<td>SC injection</td>
<td>SC injection</td>
</tr>
</tbody>
</table>
### Study intervention name

<table>
<thead>
<tr>
<th></th>
<th>Efpeglenatide</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dosing instructions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The injection interval of the IMP is once weekly on the same week day (eg, each Monday) at any time of the day. Injections should be administered SC to the abdomen, thigh or upper arm. For each injection, the date, time, and region of administration should be recorded. Within any selected region, the site of injection should be changed (rotated) at each administration to prevent skin reactions. For selected visits during the treatment period up to Week 30 (corresponding to predose PK sample collection), the weekly dose will be administered at the site after blood sample collection (see SoA, Section 1.3). For the other weekly administrations, if a dose is missed, participants must be instructed to administer it as soon as possible, if there are at least 3 days (72 hours) until the next scheduled dose. If less than 3 days remain before the next scheduled dose, participants should skip the missed dose and administer the next dose on the regularly scheduled day. In each case, participants should then resume their regular once weekly dosing schedule. The day of weekly administration can be changed if necessary as long as the last dose was administered 3 or more days before. Predose PK samples are expected to be collected at least 6 to 7 days after the last dose of IMP. The corresponding study visits (Visit 5, Visit 8, Visit 10, and Visit 11) and the timing of dose administration before each of these visits should be scheduled to ensure, as much as possible, the duration of 6 to 7 days between them is maintained.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### IMP dose schedule

<table>
<thead>
<tr>
<th>Dose 1</th>
<th>Dose 2</th>
<th>Dose 3</th>
<th>Dose 4</th>
<th>Dose 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosing</td>
<td>Day 1 Visit 3</td>
<td>Week 1 Visit 4</td>
<td>Week 2 Visit 5</td>
<td>Week 3 Visit 6</td>
</tr>
<tr>
<td>(on-site)</td>
<td>(at home)</td>
<td>(on-site)</td>
<td>(at home)</td>
<td>(on-site)</td>
</tr>
<tr>
<td>Efpeglenatide 2 mg</td>
<td>2 mg</td>
<td>2 mg</td>
<td>2 mg</td>
<td>2 mg</td>
</tr>
<tr>
<td>Efpeglenatide 4 mg</td>
<td>2 mg</td>
<td>2 mg</td>
<td>4 mg</td>
<td>4 mg</td>
</tr>
<tr>
<td>Efpeglenatide 6 mg</td>
<td>2 mg</td>
<td>2 mg</td>
<td>4 mg</td>
<td>4 mg</td>
</tr>
<tr>
<td>Placebo</td>
<td>Placebo</td>
<td>Placebo</td>
<td>Placebo</td>
<td>Placebo</td>
</tr>
</tbody>
</table>

From Week 4 (Visit 5) through the rest of the double-blind treatment period, participants will remain on the randomized IMP dose or placebo until the EOT at Week 30.

### Storage conditions

Store between +2°C and +8°C (36°F and 46°F). Do not freeze, protect from light.

### Packaging and labeling

IMP will be provided in boxes in accordance with the administration schedule. The content of the labeling is in accordance with the local regulatory specifications and requirements.

---

The details of this table are specific to IMP; information of non-IMP is described separately in this section.

EOT: end of treatment; IMP: investigational medicinal product; NA: not applicable; PFS: prefilled syringe; PK, pharmacokinetic; SC: subcutaneous; SoA, Schedule of Activities.

### 6.1.1 INVESTIGATIONAL MEDICINAL PRODUCTS

The appropriate number of kits will be dispensed for the period until the next dispensing visit (please refer to the SoA, Section 1.3). Storage conditions and use-by-end date (when required by country regulations) are part of the label text.
Participants will be trained on the use of the PFS by the study staff at Visit 2 (Week -1) and provided with an “instructions for use” leaflet, which will describe the handling procedures for the PFS and administration technique. The injection training pads can be used, if needed. Initial injection technique training at Visit 2 (Week -1) will include mandatory self-injection with a training PFS and assessment of participant’s skills and understanding by observing teach-back. If needed, an additional training PFS can be used for self-injection technique training any time prior to the day of randomization.

Review of injection technique can be done at any other visit as needed (self-injection with IMP at site during selected visits until Week 30).

Review of injection sites will be performed at all on-site visits.

Prefilled syringe-related issues (malfunctions) should be reported to the Sponsor by the means of a procedure on Product Technical Complaint forms, which are described in a separate study document.

6.1.2 NONINVESTIGATIONAL MEDICINAL PRODUCT

6.1.2.1 Background medication

Metformin/Sulfonylurea

Participants are enrolled with a background therapy consisting of metformin alone or in combination with SU. Background metformin and SU are considered as NIMPs. Metformin and SU (commercial formulations) will be administered orally according to the locally approved label.

The dose of metformin, if taken as the only OAD, must be of ≥1500 mg/day (or as per country regulation if less) or maximum tolerated dose (maximum tolerated dose needs to be documented).

The dose of SU, if taken, must be at least half of maximum recommended dose according to national label. Participants are enrolled with their antidiabetic background therapy taken at a stable dose for at least 3 months prior to the Screening visit. Doses of metformin and, if applicable, SU should be kept stable throughout the study unless dose reduction is needed for safety reasons.

In participants with HbA1c <8% at screening, the dose of SU is allowed to be decreased by at least 25% at randomization (according to investigator’s clinical judgment) in order to decrease the risk of hypoglycemia. For these patients, in case of uncontrolled SMPG values between Week 6 (Visit 6) and Week 12 (Visit 8), the SU dose can be progressively increased up to the Screening dose unless occurrence of hypoglycemia prevents this. Increasing the SU dose up to the screening dose level is not considered as rescue therapy.

In participants with HbA1c ≥8 % at screening, no SU dose adjustment is required at randomization.
Study participants, especially those on SU, must be educated to recognize and manage hypoglycemia. They also must be informed about the importance of adherence to dietary instructions (avoid deficient caloric intake). After randomization, once the double-blind study medication is added and increasingly contributing to the glucose-lowering activity, the risk of hypoglycemia may increase. In order to prevent hypoglycemia, a reduction of the SU dose might be considered in, for example in the following situations:

- Fasting (prebreakfast) SMPG below 100 mg/dL as a result of a consistently falling trend observed in the preceding 7 days
- Fasting (prebreakfast) SMPG below 80 mg/dL
- In case of 2 or more symptomatic or 1 severe hypoglycemic episode

### 6.1.2.2 Rescue Therapy

Rescue medication(s) that will be used to treat unacceptable hyperglycemia if a participant’s glycemia reaches an applicable rescue threshold is considered NIMP for this study. The threshold values are defined in Table 3, and are dependent on study period.

<table>
<thead>
<tr>
<th>Time in study</th>
<th>Threshold</th>
</tr>
</thead>
<tbody>
<tr>
<td>From randomization up through the scheduled Week 8 visit (Visit 7)</td>
<td>FPG &gt;15.0 mmol/L (&gt;270 mg/dL)</td>
</tr>
<tr>
<td>After the Week 8 visit up through the scheduled Week 12 visit (Visit 8)</td>
<td>FPG &gt;13.3 mmol/L (&gt;240 mg/dL)</td>
</tr>
<tr>
<td>After the Week 12 visit through the end of the 30-week treatment period</td>
<td>FPG &gt;11.1 mmol/L (&gt;200 mg/dL) or HbA1c ≥8.5%</td>
</tr>
</tbody>
</table>

FPG fasting plasma glucose; HbA1c hemoglobin A1c

Routine fasting SMPG and central laboratory alerts on FPG (and HbA1c from Week 12 [Visit 8] onwards) will be set up to ensure that glycemic parameter results remain below the predefined thresholds.

If a fasting SMPG value exceeds the specific glycemic limit on 1 day, the participant must check it again during the following 2 days. If all the SMPG values in 3 consecutive days exceed the specific limit, the participant should contact the Investigator and a central laboratory FPG measurement (and HbA1c from Week 12 onwards) be performed as soon as possible for confirmation.

Upon receipt of a central laboratory alert for either FPG or HbA1c, a central laboratory retest must be completed and confirmed as exceeding the threshold for rescue before rescue therapy is initiated. The retest confirmation should be performed as soon as possible during an unscheduled visit.
In the event that a confirmatory FPG and/or HbA1c value exceeds the threshold, the Investigator should ensure that no reasonable explanation exists for insufficient glucose control and in particular that:

- The increased FPG has been tested at a fasting status (ie, no food or liquid intake [except water] for ≥8 hours)
- IMP was given at the planned dose and was appropriately injected (as per weekly schedule)
- There was no intercurrent disease, which may jeopardize glycemic control (eg, infectious disease)
- Compliance to treatment was appropriate
- Compliance to diet and lifestyle was appropriate

If any of the above-mentioned explanations can reasonably explain the insufficient glycemic control, the Investigator should consider not initiating rescue medication(s) and should undertake appropriate action as follows, ie:

- Assess FPG (ie, after the participant has fasted for ≥8 hours)
- Initiate an evaluation and treatment of intercurrent disease (to be reported in the AE/concomitant medication parts of the electronic Case Report Form (eCRF) and the medical record)
- Stress the absolute need for the participant to be compliant with treatment
- Organize a specific interview with the participant and a Registered Dietician or other qualified nutrition professional to reinforce the absolute need to be compliant with diet and lifestyle recommendations, and schedule an FPG/HbA1c assessment at the next visit

If none of the above-mentioned reasons can be found, or if an appropriate action fails to decrease FPG/HbA1c below the threshold values, rescue medication(s) may be introduced.

If a participant needs to start rescue therapy, an unscheduled in-person visit will be scheduled to perform prerescue assessments (which are the same as those specified for EOT, Week 30, Visit 12) prior to starting the rescue medication(s).

Prescription of open-label rescue medication(s) to treat hyperglycemia will be at the discretion of the Investigator and in accordance with local standard of care and prescribing practice. With the exception of other GLP-1 RAs and DPP-4 inhibitors, any approved medications (including increase of prior metformin or SU dose) can be prescribed to treat the hyperglycemia. Increasing the SU dose up to the Screening dose level is not considered as rescue therapy in participants whose SU dose was temporarily decreased for HbA1c <8.0% at Week -1 or for hypoglycemia.

If a participant requires glycemic rescue, the IMP received during the randomized, double-blind treatment period should be continued and must remain blinded until the end of the study (unless the Investigator considers a change necessary for safety reasons).
All concomitant antidiabetic medications (background OAD[s] and/or rescue therapy) will be documented in the eCRF.

The cost of NIMPs not covered by health insurance will be reimbursed by the study Sponsor where permitted by local regulations.

6.2 PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY

Investigators or other authorized persons (eg, pharmacists) are responsible for storing the IMP in a secure and safe place in accordance with local regulations, labeling specifications, policies, and procedures.

Control of IMP storage conditions, especially control of temperature (eg, refrigerated storage) and information on in-use stability and instructions for handling the Sanofi compound should be managed according to the rules provided by the Sponsor.

The expiry date is mentioned on the IMP labels (when required by country regulation), and storage conditions are written on the IMP labels and in the instruction leaflet.

The Investigator or designee must confirm appropriate temperature conditions have been maintained during transit for all study IMP received and any discrepancies are reported and resolved before use of the study intervention.

Only participants enrolled in the study may receive study intervention and only authorized site staff may supply or administer study IMP. All study IMP must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to the Investigator and authorized site staff.

The Investigator, institution, or the head of the medical institution (where applicable) is responsible for study IMP accountability, reconciliation, and record maintenance (ie, receipt, reconciliation, and final disposition records).

Further guidance and information for the final disposition of unused study IMP are provided in separate study document.

The Investigator, the hospital pharmacist, or other personnel allowed to store and dispense the IMP will be responsible for ensuring that the IMP used in the clinical trial is securely maintained as specified by the Sponsor and in accordance with applicable regulatory requirements. All IMPs will be dispensed in accordance with the Investigator’s prescription and it is the Investigator’s responsibility to ensure that an accurate record of IMP issued and returned is maintained.

Any quality issue noticed with the receipt or use of an IMP/NIMP/device (deficiency in conditions, appearance, pertaining documentation, labeling, expiration date, etc) must be promptly notified to the Sponsor. Some deficiencies may be recorded through a complaint procedure (see Section 8.3.8).
A potential defect in the quality of IMP/NIMP/device may be subject to initiation of a recall procedure by the Sponsor. In this case, the Investigator will be responsible for promptly addressing any request made by the Sponsor, in order to recall the IMP/NIMP/device and eliminate potential hazards.

Under no circumstances will the Investigator supply IMP/NIMP/device to a third party, allow the IMP/NIMP/device to be used other than as directed by this clinical trial protocol, or dispose of IMP/NIMP/device in any other manner.

6.3 MEASURES TO MINIMIZE BIASES: RANDOMIZATION AND BLINDING

All participants will be centrally assigned to randomized study IMP using interactive response technology (IRT) as summarized in the SoA (Section 1.3). Before the study is initiated, instructions on how to access IRT will be provided to each site.

A randomized participant is a participant who has been randomly allocated to a study IMP, regardless whether the IMP kit was used or not. A participant cannot be randomly assigned more than once in the study.

Returned study IMP should not be redispensed to the participants.

6.3.1 Methods of blinding

During the entire double-blind treatment period, Investigators and participants will be blinded to the allocation of active or placebo treatment arms. Efpeglenatide and placebo will be provided in indistinguishable PFSs, in identical kits. Each titration and treatment kit (and the corresponding syringes) will be labeled with a unique number. The list of kit numbers will be generated by Sanofi.

In accordance with the double-blind design, Investigators will remain blinded to IMP and will not have access to the randomization (treatment) codes except under exceptional medical circumstances.

Members of the CEC will review and adjudicate events in a blinded manner (please also refer to Appendix 1 [Section 10.1]).

The Investigator will not have access to the data of the primary efficacy endpoint (i.e., HbA1c) or FPG obtained after the baseline/randomization visit (Visit 3) as those data will be masked. If the central laboratory detects FPG greater than the rescue thresholds, the Investigator will receive an alert from the central laboratory (see Section 6.1.2.2). The HbA1c alerts will also be sent if a value is greater than the threshold from the Week 12 visit (Visit 8) onwards.
6.3.2 Randomization code breaking during the study

The blind may be broken if, in the opinion of the Investigator, it is in the participant’s best interest for the Investigator to know the IMP assignment. The Sponsor must be notified before the blind is broken unless identification of the IMP is required for a medical emergency in which the knowledge of the specific blinded study treatment will affect the immediate management of the participant’s conditions (eg, antidote available). In this case, the Sponsor must be notified within 24 hours after breaking the blind. The date and reason that the blind was broken must be recorded in the source documentation and eCRF, as applicable.

Code breaking can be performed at any time by using the proper module of the IRT and/or by calling any other phone number provided by the Sponsor for that purpose. If the blind is broken, the Investigator should document the date, time of day and reason for code breaking. If the code is broken by the Investigator, the participant must withdraw from IMP administration. When documenting the reason for unblinding, the Investigator must not provide any detail regarding the nature of the IMP. The Investigator should not divulge IMP details to the Sponsor’s representative or to any staff members until database closure. Furthermore, when completing forms (eg, AE, SAE, adjudication information), the study treatment should not be disclosed on the forms.

Randomization code breaking will also be performed during the analysis of the PK serum concentration samples and ADA samples in order to enable the laboratory to sort the samples (verum [dose group], placebo) and start analyzing the samples (verum group only) while the study is still ongoing. Only the Project Manager and lead scientist at the Bioanalytical laboratory, as well as the popPK analyst, will have access to the randomization code to allow for the sorting of the efpeglenatide blood samples. The Bioanalytical laboratory and responsible personnel will follow the standard procedures to ensure the protection of the blind within the Sponsor’s clinical team. The randomization code or the individual analytical results will not be disclosed to any clinical team personnel prior to the database lock.

The DMC will receive unblinded safety data from an independent statistician for review, which will be handled strictly confidentially. None of these reports may be delivered to unauthorized persons (Appendix 1 [Section 10.1]).

Refer to Section 8.3.4 for suspected unexpected serious adverse reaction (SUSAR) unblinding by the Sponsor.

6.4 STUDY INTERVENTION COMPLIANCE

Measures taken to ensure and document treatment compliance and IMP/NIMP accountability include the following:

- Proper recording of treatment kit number as required on appropriate eCRF page for accounting purposes
- All medication treatment kits (whether empty or unused) will be returned by the participant at each visit when treatment dispensing is planned
The Investigator or his/her delegate will track treatment accountability/compliance by comparing the treatment kit number recorded on the patient diary with the treatment kit number of returned treatment kits (whether empty or unused) and completes the participant treatment log.

The monitor in charge of the study will then check the data entered on the IMPs administration page of the eCRF by comparing them with the IMPs that have been retrieved and the participant treatment log form.

For the NIMP not provided by the Sponsor, tracking and reconciliation will be documented in participant’s source documents and medication reported in appropriate eCRF pages.

### 6.4.1 Return and/or destruction of treatments

A detailed treatment log of the destroyed IMP will be established with the Investigator (or the pharmacist) and countersigned by the Investigator and the monitoring team. The Investigator will not destroy the used and unused IMP unless the Sponsor provides written authorization. For NIMP reimbursed by the Sponsor, tracking and reconciliation will be achieved by the Investigator (or the pharmacist, if appropriate) as per local requirements.

Sharp containers containing all used PFSs will be brought back to the site by the study participant for the purpose of destruction.

Destruction is strongly encouraged at site level, nevertheless, if the site is not able to destroy or destruction is not allowed in the country, all treatments kits will be retrieved by the Sponsor.

### 6.5 CONCOMITANT THERAPY

The following treatments are prohibited during the study (including during screening period and the 30 weeks of the treatment period):

- Initiation of any antidiabetic agents, other than the IMP, or increase in dose of preexisting OAD(s), before pre-rescue assessments and initiation of rescue therapy (short-term use [<10 consecutive days] of short-acting insulin for treatment of acute illness or surgery is allowed)
- Initiation of any GLP-1 RAs (eg, exenatide, liraglutide, dulaglutide, or semaglutide) and DPP-4 inhibitors (eg, sitagliptin, saxagliptin, vildagliptin, or linagliptin)
- Initiation of any prescription weight-loss drugs (eg, phentermine, lorcaserin, or orlistat)
- Gastric surgery or other gastric procedures for weight loss
- Systemic use of glucocorticoids for more than 10 consecutive days (topical, nasal spray, inhaled, or intra-articular applications are allowed)
- Any investigational drug other than IMP for this study
Glucagon-like peptide-1 receptor agonists are known to decelerate gastric emptying. The delay of gastric emptying may impact absorption of concomitantly administered oral medicinal products. As drug-drug interaction data are not yet available for efpeglenatide, caution should be exercised. Drug levels of oral medications with narrow therapeutic index should be adequately monitored.

Any medication or vaccine (including over-the-counter or prescription medicines, vitamins, and/or herbal supplements) that the participant is receiving at the time of enrollment or receives during the study must be recorded along with:

- Reason for use
- Dates of administration including start and end dates
- Dosage information including dose and frequency

6.6 DOSE MODIFICATION

Up-titration of IMP from randomization to Week 4 is described in Table 2. From Week 4 (Visit 5) through the rest of the double-blind treatment period, participants will remain on the randomized IMP (efpeglenatide assigned dose or placebo) until the EOT at Week 30 (Visit 12).

6.7 INTERVENTION AFTER THE END OF THE STUDY

The IMPs will not be provided after the end of the treatment period.

When a participant’s participation in the trial ends, the participant will consult with his/her Investigator to decide on the best available treatment.
7 DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL

Withdrawal of consent for treatment should be distinguished from (additional) withdrawal of consent for follow-up visits and from withdrawal of consent for non-participant contact follow-up (eg, medical record checks). The site should document any case of withdrawal of consent.

7.1 DISCONTINUATION OF STUDY INTERVENTION

The IMP should be continued whenever possible.

In case the IMP is stopped, it should be determined whether the stop can be made temporarily; permanent IMP discontinuation should be a last resort. Any IMP discontinuation must be fully documented in the eCRF. In any case, the participant should remain in the study as long as possible to collect endpoint data at Week 30 vital safety status at the scheduled end of study.

7.1.1 Permanent discontinuation

Permanent IMP discontinuation is any IMP discontinuation associated with the definitive decision from the Investigator not to re-expose the participant to the IMP at any time during the study, or from the participant not to be re-exposed to the IMP whatever the reason.

The participants may withdraw from treatment with IMP if they decide to do so, at any time, and irrespective of the reason. Participants should discuss stopping the IMP with the site before doing so in order that questions can be addressed, concomitant therapy can be adjusted if needed, and a follow-up assessment arranged. All efforts should be made to document the reasons for treatment discontinuation and this should be documented in the eCRF.

A participant should withdraw from treatment with IMP in case of the following:

- Intercurrent conditions that require discontinuation of IMP: eg, laboratory abnormalities (see decision tree and general guidance for the follow-up of laboratory abnormalities in Appendix 6 [Section 10.5]), diagnosis of acute pancreatitis confirmed by gastroenterologic evaluation and imaging, unless a clear cause unrelated to IMP is confirmed and the participant has recovered from pancreatitis (see Appendix 7 [Section 10.5.2]), or calcitonin value ≥50 pg/mL (see Appendix 7 [Section 10.5.3]).

- If, in the Investigator’s opinion, continuation with the administration of IMP would be detrimental to the participant’s well-being

- Pregnancy (in female participants)

- Confirmed intolerance to the allocated dose of IMP

- Any code breaking requested by the Investigator

- At the specific request of the Sponsor
As all data until the scheduled date of study completion will be used in statistical analyses, it is important to collect data for all participants, under treatment or not, during the 30 weeks of the study. A high rate of missing data could jeopardize efficacy results of the study. Refer to the SoA (Section 1.3) for data to be collected at the time of IMP discontinuation and follow-up and for any further evaluations that need to be completed.

Any abnormal laboratory value or ECG parameter will be immediately rechecked for confirmation (as soon as possible, preferably within 24 hours) before making a decision of permanent discontinuation of the IMP for the concerned participant.

Handling of participants after permanent intervention discontinuation

Every effort should be made to maintain participants in the study. Participants will be followed according to the study procedures specified in this protocol up to the scheduled date of study completion, or up to recovery or stabilization of any AE to be followed as specified in this protocol, whichever comes last.

If possible, the participants will be assessed using the procedure normally planned for the EOT Visit, including a PK sample if this visit can be scheduled 6 to 7 days after the permanent discontinuation of IMP. For participants who discontinue IMP but remain in the study, the remaining visits should occur as scheduled where possible. The Investigators should discuss with the key visits to attend. All efforts should be made to continue to follow the participants for primary and secondary endpoints, after the discontinuation of IMP.

The value of all their study data collected during their continued involvement will be emphasized as important to the public health value of the study. Participants who withdraw from the study IMP should be explicitly asked about the contribution of possible AEs to their decision and any AE information elicited must be documented.

All cases of permanent study IMP discontinuation must be recorded by the Investigator in the appropriate pages of the eCRF when considered as confirmed.

7.1.2 Temporary discontinuation

Temporary IMP discontinuation corresponds to at least 1 (one) dose not administered to the participants.

All IMP discontinuation should initially be considered as temporary unless permanent discontinuation is mandated by the protocol (see Section 7.1), and the Investigator should make best effort to resume IMP treatment as early as practically possible. There is no defined limit to the duration of temporary discontinuation.

Temporary IMP discontinuation may be considered by the Investigator because of suspected AEs (including intolerance to IMP planned dose). For all temporary IMP discontinuations, duration should be recorded by the Investigator in the appropriate pages of the eCRF.
7.1.3 Rechallenge

Reinitiation of treatment with the IMP will be done under close and appropriate clinical/and or laboratory monitoring once the Investigator will have considered according to his/her best medical judgment that it is safe for the participant to restart the IMP. In case of IMP intolerance, a one-time rechallenge is recommended following temporary discontinuation before deciding to permanently discontinue the IMP. If a maximum of 2 consecutive doses are missed, the IMP can be restarted with the last dose given. In cases where 3 or more consecutive doses are missed, the titration should be reinitiated.

Participants who temporarily discontinue IMP should be reassessed at every visit to determine whether it is possible to safely resume IMP. If a decision has been made that the discontinuation is permanent, then the participant should be considered as permanently discontinued and the corresponding eCRF page should be completed. Please note that permanent discontinuation should be a last resort.

7.2 PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY

A participant may withdraw from the study at any time at his/her own request, or may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons.

If the participant withdraws consent for disclosure of future information, the Sponsor may retain and continue to use any data collected before such a withdrawal of consent.

If a participant withdraws from the study, he/she may request destruction of any samples taken and not tested, and the Investigator must document this in the site study records.

Refer to the SoA (Section 1.3) for data to be collected at the time of study discontinuation and follow-up and for any further evaluations that need to be completed.

All study withdrawals should be recorded by the Investigator in the appropriate screens of the eCRF and in the participant’s medical records. In the medical record, at least the date of the withdrawal and the reason should be documented.

Participants who have withdrawn from the study cannot be rerandomized (treated) in the study. Their inclusion and randomization numbers must not be reused.
7.3 LOST TO FOLLOW UP

A participant will be considered lost to follow-up if he/she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site.

The following actions must be taken if a participant fails to return to the clinic for a required study visit:

- The site must attempt to contact the participant and reschedule the missed visit as soon as possible and counsel the participant on the importance of maintaining the assigned visit schedule and ascertain whether or not the participant wishes to and/or should continue in the study.

- Before a participant is deemed as lost to follow-up, the Investigator or designee must make every effort to regain contact with the participant (where possible, 3 telephone calls and, if necessary, a certified letter to the participant’s last known mailing address or local equivalent methods). These contact attempts should be documented in the participant’s medical record.

- Should the participant continue to be unreachable, he/she will be considered to have withdrawn from the study.
8 STUDY ASSESSMENTS AND PROCEDURES

- Study procedures and their timing are summarized in the SoA (Section 1.3). Protocol waivers or exemptions are not allowed.
- Immediate safety concerns should be discussed with the Sponsor immediately upon occurrence or awareness to determine if the participant should continue or discontinue study IMP.
- Adherence to the study design requirements, including those specified in the SoA (Section 1.3), is essential and required for study conduct.
- All screening evaluations must be completed and reviewed before confirming Visit 2 in IRT, to confirm that potential participants meet all eligibility criteria. Eligibility criteria will be evaluated again before randomization, including additional criteria at the end of the screening period (see Section 5.1 and Section 5.2). The Investigator will maintain a screening log to record details of all participants screened and to confirm eligibility or record reasons for screening failure, as applicable.

8.1 EFFICACY ASSESSMENTS

8.1.1 Hemoglobin A1c

The primary efficacy endpoint and 1 secondary efficacy endpoint are assessed by the measurement of HbA1c. For the eligibility and efficacy assessments of the study, HbA1c is measured at different time points during study, by a certified level I “National Glycohemoglobin Standardization Program” central laboratory.

If a participant needs to receive rescue therapy (see Section 6.1.2.2), then the HbA1c assessment should be performed before the introduction of rescue medication(s).

8.1.2 Fasting plasma glucose

Plasma glucose will be assessed in a fasted state (as defined in Section 5.3.1) according to the schedule detailed in the SoA (Section 1.3). If participant is not fasting at the time of the visit, a retest should be scheduled in a fasting state for the next day (or as soon as possible). For the efficacy assessments of the study, FPG is measured at a central laboratory.

8.1.3 Body weight

Body weight will be measured to allow the estimation of change from baseline to Week 30 in body weight.

Body weight is measured at every on-site study visit, with the participant wearing only undergarments or very light clothing and no shoes, and with an empty bladder.
The same scale should be used throughout the study and calibrated on a regular basis as recommended by the manufacturer. Calibration should be documented in source documents.

The use of balance scales is recommended; if digital scales are used, testing with standard weights is of particular importance. The floor surface on which the scale rests must be hard and should not be carpeted or covered with other soft material. The scale should be balanced with both weights at zero and the balance bar aligned. The participant should stand in the center of the platform as standing off-center may affect measurement. The weights must be moved until the beam balances (the arrows are aligned). The weight must be read and recorded in the eCRF and source documents. Self-reported weights are not acceptable; participants must not read the scales themselves.

8.1.4 7-point self-monitored plasma glucose profiles

The 7-point SMPG will be performed over a single 24-hour period, on at least 1 day within the weeks prior to selected study visits (see SoA, Section 1.3), and must be recorded in the patient diary. Participants should repeat the 7-point SMPG profile if any time point is missed.

The 7-point SMPG profile should be measured at the following 7 points: prebreakfast and 2 hours postbreakfast, prelunch and 2-hour postlunch, predinner and 2-hour postdinner, and at bedtime. Two hours postprandial (breakfast, lunch, and dinner) is defined as 2 hours after the start of the meal.

On days when 7-point SMPG profiles are measured, the fasting prebreakfast SMPG profile will be considered as the first point of measurement, ie, “prebreakfast” time point.

8.1.5 Use of rescue therapy

The use of rescue medication(s) for hyperglycemia will be assessed and reported throughout the treatment period to allow determination of the start of rescue therapy and the percentage of participants using rescue therapy at Week 30. Routine fasting SMPGs will be measured by the participants, and alerts on FPG and/or HbA1c will be sent from the central laboratory to the Investigator to ensure that glycemic parameter results remain within predefined thresholds. For details and further actions should FPG and/or HbA1c values rise to values greater than the predefined thresholds, refer to Section 6.1.2.2.
8.2 SAFETY ASSESSMENTS

The planned time points for all safety assessments are provided in the SoA (Section 1.3).

8.2.1 Physical examinations

- A complete physical examination will be performed as per clinical practice in order to assess the health status of the participant at screening and evaluate the inclusion/exclusion criteria.
- At the other selected on-site visits, a limited physical examination focused on any affected body area or organ system and other symptomatic or related organ system(s) will be performed.
- Height will be measured at screening only. If for any reason it was not measured at this visit, it can be measured at any other visit in the study.
- Investigators should pay special attention to clinical signs related to previous serious illnesses.
- Any new finding or worsening of previous finding should be reported as a new AE.

8.2.2 Vital signs

- Blood pressure and pulse measurements will be assessed while the participant is in a seated position using the same device (automated BP monitor or a manual sphygmomanometer) for each participant.
- At the Screening Visit (Visit 1), BP will be measured on both arms to identify and select the appropriate arm for future measurements. Seated BP should be measured in both arms after at least a 5-minute rest period, and then again after 1 minute in both arms while the participant is in a seated position. The arm with the highest systolic BP will be determined at this visit and BP should be measured in this arm throughout the study. This highest value will be recorded in the eCRF.
- At subsequent visits, BP and pulse measurements are to be performed using the participants’ identified appropriate arm and should be preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (eg, television, cell phones).
- Heart rate will be measured at the time of the measurement of seated BP.
8.2.3 Electrocardiograms

8.2.3.1 12-lead electrocardiogram

A 12-lead ECG recording will be performed locally as scheduled in the SoA (see Section 1.3).

The 12-lead ECG should be performed after the participant has been in the supine position for at least 10 minutes and prior to other study procedures at that visit (eg, blood collection, IMP administration). The Investigator should review the ECG trace and document the interpretation, sign and date the ECG print out and record it in the eCRF. Each ECG trace must be compared with the screening ECG results. All original ECG traces must be kept as source data. The ECG assessment of “normal” or “abnormal” will be analyzed.

Note: Any new ECG abnormality should be rechecked for confirmation and reported as an AE if considered clinically significant by the Investigator.

8.2.4 Clinical safety laboratory assessments

See Appendix 2 (Section 10.2) for the list of clinical laboratory tests to be performed and to the SoA (Section 1.3) for the timing and frequency of sample collection.

- The Investigator must review the laboratory report, document this review, and record any clinically relevant changes occurring during the study in the AE section of the eCRF. The laboratory reports must be filed with the source documents. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the Investigator to be more severe than expected for the participant’s conditions.

- All laboratory tests with values considered clinically significantly abnormal during participation in the study should be repeated until the values return to normal or baseline or are no longer considered clinically significant by the Investigator or medical monitor.
  
  - If such values do not return to normal or baseline within a period of time judged reasonable by the Investigator, the etiology should be identified and the Sponsor notified.

All protocol-required laboratory assessments, as defined in Appendix 2 (Section 10.2), must be conducted in accordance with the laboratory manual and the SoA (Section 1.3).

- If local laboratory results are used to make study treatment decision, for response evaluation, or to diagnose/follow-up an AE, then the results must be recorded in the eCRF.

- Recommended decision trees for the management of certain laboratory abnormalities are provided in Appendix 5 (Section 10.5).
8.2.5 Hypoglycemia

During the study, participants must be instructed to document any hypoglycemic episodes in their study diary. Hypoglycemia will be reported in the specific hypoglycemia event information form of the eCRF page with onset date and time, symptoms and/or signs, the SMPG value if available, and the treatment. Hypoglycemia fulfilling the seriousness criteria must be documented in addition on the SAE form in the eCRF.

Hypoglycemic events will be categorized (6, 7, 8) as follows (also see Appendix 8 [Section 10.8]):

- **Severe hypoglycemia**: Severe hypoglycemia is an event requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure, unconsciousness, or coma. Plasma glucose measurements may not be available during such an event, but neurological recovery attributable to the restoration of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration. The definition of severe symptomatic hypoglycemia includes all episodes in which neurological impairment was severe enough to prevent self-treatment and which were thus thought to place participants at risk for injury to themselves or others. Note that “requiring assistance of another person” means that the participant could not help himself or herself. Assisting a participant out of kindness, when assistance is not required, should not be considered a “requiring assistance” incident. Severe hypoglycemia will be reported as an SAE only if it fulfills SAE criteria (see Appendix 3 [Section 10.3]). For example, events of seizure, unconsciousness or coma must be reported as SAEs.

- **Documented symptomatic hypoglycemia**: Documented symptomatic hypoglycemia is an event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration less than or equal to 3.9 mmol/L (70 mg/dL). Clinical symptoms that are considered to result from a hypoglycemic episode are, eg, increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, or coma.

- **Asymptomatic hypoglycemia**: Asymptomatic hypoglycemia is an event not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration less than or equal to 3.9 mmol/L (70 mg/dL).

- **Probable symptomatic hypoglycemia**: Probable symptomatic hypoglycemia is an event during which symptoms of hypoglycemia are not accompanied by a plasma glucose determination, but was presumably caused by a plasma glucose concentration less than or equal to 3.9 mmol/L (70 mg/dL); symptoms are treated with oral carbohydrate.

- **Relative hypoglycemia**: (recently termed “pseudohypoglycemia”) is an event during which the person with diabetes reports any of the typical symptoms of hypoglycemia, and interprets the symptoms as indicative of hypoglycemia, but with a measured plasma glucose concentration greater than 3.9 mmol/L (70 mg/dL).
In addition to the threshold of plasma glucose of less than or equal to 3.9 mmol/L (70 mg/dL), documented hypoglycemia with a measured plasma glucose concentration less than 3.0 mmol/L (54 mg/dL) will also be analyzed (8).

Hypoglycemic events will be evaluated regardless of the time of onset during the study and time of the day.

In addition, hypoglycemic events will be evaluated at the following time periods defined by time of the day:

- **Nocturnal hypoglycemia defined by time of the day**: any hypoglycemia of the above categories that occurs between 00:00 and 05:59, regardless of whether participant was awake or woke up because of the event
- **Daytime hypoglycemia**: any hypoglycemia of the above categories that occurs between 06:00 and 23:59

### 8.3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS

**Adverse event of special interest**

An adverse event of special interest (AESI) is an AE (serious or non-serious) of scientific and medical concern specific to the Sponsor’s product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor is required. Such events may require further investigation in order to characterize and understand them. The classification of AESI may be changed during the study by protocol amendment (eg, further AE classified as AESI, or AE losing their AESI status).

- Pregnancy of a female participant entered in a study as well as pregnancy occurring in a female partner of a male participant entered in a study with IMP/NIMP (see Section 8.3.5);
  - In the event of pregnancy in a female participant, IMP should be discontinued
- Symptomatic overdose (serious or nonserious) with IMP/NIMP:
  - An overdose (accidental or intentional) with the IMP is an event suspected by the Investigator or spontaneously notified by the participant and defined as at least twice the planned dose (eg, two or more injections) if given within 3 days (72 hours)
  - An overdose (accidental or intentional) with the NIMP is an event suspected by the Investigator or spontaneously notified by the participant and defined as at least twice the recommended dose during the planned interval(s)
  - Of note, asymptomatic overdose has to be reported as a standard AE
- Increase in ALT >3 × ULN (see Appendix 5 [Section 10.5])

The definitions of an AE or SAE can be found in Appendix 3 (Section 10.3).

Adverse events will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative).
The Investigator and any qualified designees are responsible for detecting, documenting, and recording events that meet the definition of an AE or SAE and remain responsible for follow-up AEs that are serious, considered related to the study IMP or study procedures, or that caused the participant to discontinue the study IMP and/or study (see Section 7).

**Adverse events requiring specific monitoring**

An AE requiring specific monitoring is a serious or nonserious AE of scientific and medical concern specific to the Sponsor’s product or program, for which ongoing monitoring may be appropriate. Such events may require further investigation to characterize and understand them. These events should be reported on the AE page and additional information required on the specific eCRF page (where applicable) and will only qualify for expedited reporting when serious (fulfilling SAE criteria).

The AEs requiring specific monitoring for this study are as follows:

- Severe GI events
- Severe hypoglycemia (see Section 8.2.5)
- Pancreatic events (including abnormal values of pancreatic enzymes [see Appendix 7, Section 10.5.2]) – will be adjudicated by CEC
- Major adverse cardiovascular events (MACE; CV death, myocardial infarction, stroke) and other specific CV events (eg, heart failure leading to hospitalization) – will be adjudicated by CEC
- Calcitonin increase >5.9 pmol/L (20 pg/mL) and thyroid C-cell neoplasm (see Appendix 7, [Section 10.5.3])
- Acute renal failure (see Appendix 5 [Section 10.5] for definition)
- Diabetic retinopathy complications (will be reviewed by an independent ophthalmologist expert; see Appendix 1 [Section 10.1.4.3]); a written report from professional eye care provider will be required
- Severe injection site reaction
- Severe allergic reactions
- Severe immune complex disease

**8.3.1 Time period and frequency for collecting AE and SAE information**

All AEs, SAEs, AESIs, and AEs requiring specific monitoring will be collected from the date of signing the ICF until the end of the study as defined by the protocol for that participant, at the time points specified in the SoA (Section 1.3).

Investigators are not obligated to actively seek AEs or SAEs after conclusion of the study participation. However, if the Investigator learns of any SAE, including a death, at any time after a participant has been discharged from the study, and he/she considers the event to be reasonably related to the study IMP or study participation, the Investigator must promptly notify the Sponsor.
The method of recording, evaluating, and assessing causality of AEs and SAEs and the procedures for completing and transmitting SAE reports are provided in Appendix 3 (Section 10.3).

8.3.2 Method of detecting AEs and SAEs

Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and nonleading verbal questioning of the participant is the preferred method to inquire about AE occurrences.

8.3.3 Follow-up of AEs and SAEs

After the initial AE/SAE report, the Investigator is required to proactively follow each participant at subsequent visits/contacts. All SAEs, nonserious AESIs, and AEs requiring specific monitoring (as defined in Appendix 3 [Section 10.3]), will be followed until resolution, stabilization, the event is otherwise explained, or the participant is lost to follow-up (as defined in Section 7.3). Further information on follow-up procedures is given in Appendix 3 (Section 10.3).

8.3.4 Regulatory reporting requirements for SAEs

The following are requirements for reporting of SAEs:

- Prompt notification by the Investigator to the Sponsor of an SAE is essential so that legal obligations and ethical responsibilities towards the safety of participants and the safety of a study intervention under clinical investigation are met.

- The Sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study intervention under clinical investigation. The Sponsor will comply with country-specific regulatory requirements relating to safety reporting to the regulatory authority, Institutional Review Board (IRB)/Independent Ethics Committees (IECs), and Investigators.

- Investigator safety reports must be prepared for SUSARs according to local regulatory requirements and Sponsor policy and forwarded to Investigators as necessary.

- An Investigator who receives an Investigator safety report describing an SAE or other specific safety information (e.g., summary or listing of SAEs) from the Sponsor will review and then file the report along with the IB and will notify the IRB/IEC, if appropriate according to local requirements.

8.3.5 Pregnancy

- Details of all pregnancies in female participants and female partners of male participants will be collected after the start of study IMP and until the Follow-up Visit (Visit 12).

- If a pregnancy is reported, the Investigator should inform the Sponsor within 24 hours of learning of the pregnancy and should follow the procedures outlined in Appendix 4 (Section 10.4).

- In the event of pregnancy in a female participant, IMP should be discontinued.
- A pregnancy will be qualified as an SAE only if it fulfills 1 of the seriousness criteria (see Appendix 3 [Section 10.3]).
- Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs.

8.3.6 Cardiovascular and death events

For CV events, see details of the AEs requiring specific monitoring above.

8.3.7 Disease-related events and/or disease-related outcomes not qualifying as AEs or SAEs

Not applicable.

8.3.8 Guidelines for reporting product complaints/medical device incidents (including malfunctions)

Any defect in the IMP/NIMP/device must be reported as soon as possible by the Investigator to the monitoring team that will complete a product complaint form within the required timelines.

Appropriate information (e.g., samples, labels, or documents like pictures or photocopies) related to product identification and to the potential deficiencies may need to be gathered. The Investigator will assess whether or not the quality issue has to be reported together with an AE or SAE.

8.4 TREATMENT OF OVERDOSE

The Sponsor does not recommend specific treatment for an overdose.

In the event of an overdose, the Investigator should do the following:

1. Contact the Medical Monitor immediately.
2. Closely monitor the participant for any AE/SAE and laboratory abnormalities.
3. Document the quantity of the excess dose as well as the duration of the overdose in the eCRF.

Decisions regarding dose interruptions or modifications will be made by the Investigator in consultation with the Medical Monitor based on the clinical evaluation of the participant.
8.5 PHARMACOKINETICS

- Blood samples will be collected for measurement of serum concentrations of efpeglenatide as specified in the SoA (see Section 1.3). Instructions for the collection and handling of biological samples will be provided by the Sponsor. The actual date and time (24-hour clock time) of each sample will be recorded along with the date, time, and region (abdomen, thigh, or arm) of drug administration. Samples not collected, missed or lost, for any reason should be recorded.

- For a subset of participants, 10% of total (N=16 per group): 1 additional postdose sample will be taken either 4 days (±1 day) after 1st IMP dose, or 4 days (±1 day) after 4th dose, or 4 days (±1 day) after 12th dose. To reach this number and due to the blind design of the study, PK postdose sample will be collected in the first 130 randomized participants who will accept this additional sampling, sign the separate consent form and provide a valid postdose sample.

- The collected blood samples will be used to determine concentration of efpeglenatide in serum and these concentration data will be summarized and reported in the CSR.

- The concentrations will be used to perform a popPK analysis by nonlinear mixed effects modeling and results will be reported in separate popPK report.

- Samples collected for analyses of efpeglenatide serum concentration may also be used to evaluate safety or efficacy aspects related to concerns arising during or after the study if warranted upon agreement with the Sponsor.

Drug concentration information that may unblind the study will not be reported to investigative sites or blinded personnel.

8.6 PHARMACODYNAMICS

Pharmacodynamic parameters are not evaluated as part of this study.

8.7 GENETICS

Genetics are not evaluated in this study.

8.8 BIOMARKERS

Biomarkers are not evaluated in this study.
8.8.1 Immunogenicity assessments

Blood samples are taken to assess the ADA status (positive or negative) and level (titer). Cross reactivity of confirmed positive samples to endogenous GLP-1 (positive or negative), endogenous glucagon (positive or negative), neutralizing capacity of ADAs, and presence of antibodies against polyethylene glycol (PEG) (positive or negative) will also be evaluated in serum at the time points specified in the SoA (Section 1.3).

Participants positive for ADAs at the end of study, and who experienced severe injection site or hypersensitivity reaction at any time during the study, will be asked to provide sample for anti-efpeglenatide antibodies assessments 4 and 6 months after the EOT.

8.9 HEALTH ECONOMICS

Health Economics and Health Economics parameters are not evaluated in this study.
9 STATISTICAL CONSIDERATIONS

9.1 STATISTICAL HYPOTHESES

For the primary efficacy variable of change from baseline to Week 30 in HbA1c, the following statistical null hypothesis and alternative will be tested for each efpeglenatide dose:

- H0: No treatment difference
- H1: Efpeglenatide has a higher reduction in HbA1c from baseline than placebo

Based on data from previous Phase 1 and 2 studies and modeling, a minimum treatment effect difference of -0.6% in HbA1c change from baseline to Week 30 was considered as reasonable for this study.

9.2 SAMPLE SIZE DETERMINATION

The sample size calculations were performed based on the primary endpoint, change in HbA1c (%) from baseline to Week 30.

A sample size of 160 per arm (ie, 160 participants for each of the efpeglenatide dose and 160 for the placebo group) has >99% power to detect a treatment difference of -0.6% between each dose of efpeglenatide and placebo in HbA1c change from baseline to Week 30, assuming a common SD of 1.1% (2-sided, α=0.05) for each comparison. Furthermore, with approximately 50% of participants being on metformin alone (ie, 80 per arm) and approximately 50% on metformin + SU (ie., 80 per arm), there will be 92% (81%) power to detect a treatment difference of -0.6% (-0.5%) between each efpeglenatide dose and placebo within the subgroup of participants on metformin alone or subgroup of participants on metformin + SU.

Hence, there are 4 parallel dosing arms as follows:

- Efpeglenatide 2 mg, N=160
- Efpeglenatide 4 mg, N=160
- Efpeglenatide 6 mg, N=160
- Efpeglenatide placebo, N=160

Hierarchical procedure will be done to adjust the multiplicity of comparison.
9.3 POPULATIONS FOR ANALYSES

For purposes of analysis, the following populations are defined (Table 4):

<table>
<thead>
<tr>
<th>Population</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screened</td>
<td>All participants who sign the ICF.</td>
</tr>
<tr>
<td>Randomized</td>
<td>All screened participants who have a treatment kit number allocated and recorded in the IRT database, regardless of whether the treatment kit was used or not.</td>
</tr>
<tr>
<td>ITT</td>
<td>All participants randomized irrespective of rescue therapy use and compliance with the study protocol and procedures. Participants will be analyzed in the treatment group to which they are randomly assigned.</td>
</tr>
<tr>
<td>Safety</td>
<td>All participants randomly assigned to IMP and who take at least 1 dose of IMP. Participants will be analyzed according to the treatment they actually received.</td>
</tr>
<tr>
<td>ADA</td>
<td>All participants from the safety population with at least 1 postbaseline valid ADA sample after drug administration.</td>
</tr>
<tr>
<td>PK</td>
<td>All participants from the safety population with at least 1 valid PK sample available for analysis.</td>
</tr>
</tbody>
</table>

ADA: anti-drug antibody; ICF: informed consent form; IRT: interactive response technology; ITT: intent-to-treat; PK: pharmacokinetic

9.4 STATISTICAL ANALYSES

The statistical analysis plan will be developed and finalized before database lock and will describe the participant populations to be included in the analyses and procedures for accounting for missing, unused, and spurious data. This section is a summary of the planned statistical analyses of the primary and secondary endpoints.

9.4.1 Efficacy analyses

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Statistical Analysis Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary</td>
<td></td>
</tr>
<tr>
<td>Change from baseline to Week 30 in HbA1c</td>
<td>Primary analysis: The primary efficacy endpoint will be analyzed using all HbA1c values measured at baseline and Week 30 (observed or imputed), regardless of treatment discontinuation or initiation of rescue therapy. The primary analysis method for the primary efficacy endpoint will be an ANCOVA model with missing values imputed by MI analysis methods in 2 parts as follows: 1. Missing endpoint data for participants who prematurely discontinue the IMP before the endpoint visit will be imputed using a model estimated from the participants in the same treatment arm who prematurely discontinue the IMP before the endpoint visit but have the measurement for the endpoint (retrieved dropouts). Considering that the number of participants in each treatment arm who discontinue the IMP but have the measurement for the endpoint is expected to be small, we propose to use a simple imputation model, where only the baseline measurements are included as the predictor. Each treatment group will have their own imputation model. Missing data will be imputed using the regression method.</td>
</tr>
</tbody>
</table>
**Endpoint Statistical Analysis Methods**

2. Missing endpoint data in all participants, including those in the efpeglenatide groups, who stay on the IMP until the endpoint visit will be imputed separately, using a model estimated from participant in the placebo group who stay on the IMP until the endpoint visit and have the endpoint data available. The imputation model will include the randomization strata (screening HbA1c [<8%, ≥8%], SU use at screening [Yes/No]), and baseline HbA1c value. Missing data will be imputed using the regression method.

In this analysis, missing endpoint values will be imputed 10,000 times to generate 10,000 data sets with complete data. Each of the completed datasets after the imputation will be analyzed by the ANCOVA model with the treatment groups (efpeglenatide 2, 4, or 6 mg, placebo), randomization stratum of screening HbA1c (<8%, ≥8%), randomization stratum of screening SU (Yes/No) and country (US; China) as fixed effects, and baseline HbA1c value as a covariate. The baseline value is defined as the last available value prior to the first dose administration of IMP or the last available value on or before the date of randomization if not treated with the double-blinded IMP.

The results from the 10,000 analyses will be combined using Rubin’s formula and provide the adjusted mean change in HbA1c from baseline to Week 30 (regardless of treatment discontinuation or initiation of rescue therapy) for each treatment group, as well as the difference between each efpeglenatide dose and placebo and the 95% CI for the difference.

There may not be enough number of retrieved dropouts to support the imputation approach for the group with missing data that prematurely discontinue treatment, described above. If the number of participants who prematurely discontinue the IMP before the endpoint visit but have the measurement for the endpoint is <5 in any treatment arms, a back-up imputation method for the primary efficacy analysis will be used. In particular, missing endpoint data for all participants in both efpeglenatide and placebo groups, regardless of staying on the IMP or not, will be imputed using a model estimated from participants in the placebo group with endpoint data, where randomization strata and baseline HbA1c values are included as the predictors. Missing data will be imputed using the regression method.

A hierarchical procedure will be performed to adjust for the multiplicity of comparison on the primary endpoint as follows:

- First, the highest dose of efpeglenatide (6 mg) will be compared to placebo
- If superiority is demonstrated for the 6 mg dose of efpeglenatide, the superiority of the 4 mg dose of efpeglenatide versus placebo will be tested
- If superiority is also demonstrated for the 4 mg dose of efpeglenatide, the lowest dose (2 mg) will be tested for superiority over placebo

When superiority is not obtained in a step, the sequential testing procedure will be stopped.

**Sensitivity analysis:**

Tipping-point analysis based on the same MI method as described above will be performed to examine the robustness of the results from the primary analysis. A penalty δ will be added to participants in efpeglenatide groups (2, 4, or 6 mg) who have no HbA1c data at Week 30. The penalty will be gradually increased to evaluate at which level the conclusion of the analyses in terms of statistical significance is changed for each efpeglenatide dose group. The tipping point is the penalty level, at which the magnitude of efficacy reduction in participants without HbA1c data at Week 30 creates a shift in the treatment effect of efpeglenatide from being statistically significantly better than placebo to a non-statistically significant effect. Least squares mean difference between each efpeglenatide dose and placebo and its associated p-value will be provided for each penalty level.

Another sensitivity analysis method for the primary efficacy endpoint (change from baseline to Week 30 in HbA1c) will be an ANCOVA model with missing values imputed by control-based MI method (copy to reference) under the missing not at random framework in the ITT.
**Endpoint** | **Statistical Analysis Methods**
--- | ---
population. | - For participants in the placebo group, missing data will be imputed based on the placebo group data  
- For participants in the efpeglenatide group, missing data will be imputed as if the participants were on placebo throughout the study  

Each of the complete datasets after the imputation will be analyzed by the ANCOVA model with the treatment groups (efpeglenatide 2, 4, or 6 mg, placebo), randomization stratum of screening HbA1c (<8%, ≥8%), randomization stratum of Screening SU (Yes/No) and country as fixed effects, and baseline HbA1c value as a covariate. Same results as the primary analysis will be provided.  

Descriptive analyses will be conducted to explore missing data patterns for HbA1c in the primary efficacy analysis, with number and percentage of participants in each of the following categories presented by treatment group.  
- Pattern 1: participants without baseline values, if any  
- Pattern 2: participants with baseline values but without postbaseline values during the 30-week treatment period  
- Pattern 3: participants with baseline values and at least 1 postbaseline value during the 30-week treatment period but not at Week 30  
- Pattern 4: participants with baseline values and a Week 30 value during the 30-week treatment period  

HbA1c values by visit will be presented by missing data pattern for each treatment group, using descriptive statistics and/or graphs.  

**Assessment of treatment effect by subgroup:**  
The primary efficacy endpoint will be further analyzed to examine the consistency of the treatment effect across the subgroups defined by the following baseline covariates:  
- Race (white, black or African American, Asian, Other) (any race groups with fewer than 5 participants may be combined with “Other” category as appropriate)  
- Ethnicity (Hispanic, Not Hispanic)  
- Age group (<50, ≥50 to <65, ≥65 to <75, ≥75 years) (any category with fewer than 5 participants may be combined with another category as appropriate)  
- Gender (Male, Female)  
- Diabetes duration (<10, ≥10 years)  
- Baseline HbA1c (<8.0%, ≥8.0%)  
- SU use at screening (Yes/No)  
- Baseline BMI level (<25, ≥25 to <30, ≥30 kg/m²)  
- Country (US, China)  

The treatment effects (efpeglenatide 2, 4, or 6 mg, versus placebo) across the subgroups defined for each of these factors will be estimated for the change from baseline to Week 30 in HbA1c in the ITT population, and using a similar approach as applied to the analysis for the primary efficacy endpoint. The ANCOVA model will include treatment groups (efpeglenatide 2 mg, 4 mg, or 6 mg, placebo) and randomization stratum of screening HbA1c (<8%, ≥8%), randomization stratum of screening SU (Yes/No) and geographical region (US; China), subgroup factor, treatment-by-subgroup factor, and region as fixed factors and using baseline HbA1c value as a covariate. The adjusted estimates of treatment mean differences (each efpeglenatide dose versus placebo) with SE and 95% CIs will be provided across the subgroups, as appropriate. A graphical presentation of the results (ie, forest plot) will also be provided.
## Endpoint Statistical Analysis Methods

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Statistical Analysis Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Secondary</strong></td>
<td></td>
</tr>
<tr>
<td>Number of participants with HbA1c &lt;7.0% at Week 30</td>
<td>Continuous secondary efficacy endpoints will be analyzed using the same ANCOVA model with missing values imputed by MI method as the method used for the primary efficacy endpoint analysis. Differences between treatment groups and CIs will be estimated by this method. Categorical efficacy endpoints will be analyzed by the Cochran-Mantel-Haenszel method stratified by the randomization strata. For the HbA1c &lt;7.0% analysis, participants with missing HbA1c data at Week 30 will be considered nonresponders in the ITT population. Summary statistics (for screening value, baseline value, observed values, and observed changes from baseline) at scheduled visits will be provided for each treatment group over the whole treatment period. The summary will include the number of observations, mean, SD, SE, minimum, median, and maximum. Graphical presentations will also be used to examine trends over time using mean values (±SE) and mean changes from baseline (±SE) at each of the scheduled visits (using OCs).</td>
</tr>
<tr>
<td>Change from baseline to Week 30 in body weight and FPG</td>
<td></td>
</tr>
<tr>
<td><strong>Multiplicity considerations</strong></td>
<td>To control the family-wise type I error, a step-down testing procedure will be applied. For the primary efficacy endpoint (change from baseline to Week 30 in HbA1c), the 3 efpeglenatide doses will be tested in the order of 6 mg, 4 mg, and 2 mg. Once the primary endpoint is statistically significant at α = 0.05 (2-sided) for all 3 efpeglenatide doses, a hierarchical testing procedure will be performed to test the following study secondary efficacy endpoints by the following prioritized order:</td>
</tr>
<tr>
<td>1. HbA1c &lt;7% at Week 30 for efpeglenatide 6 mg versus placebo (Yes/No)</td>
<td></td>
</tr>
<tr>
<td>2. HbA1c &lt;7% at Week 30 for efpeglenatide 4 mg versus placebo (Yes/No)</td>
<td></td>
</tr>
<tr>
<td>3. Change from baseline to Week 30 in body weight (kg) for efpeglenatide 6 mg versus placebo</td>
<td></td>
</tr>
<tr>
<td>4. Change from baseline to Week 30 in body weight (kg) for efpeglenatide 4 mg versus placebo</td>
<td></td>
</tr>
<tr>
<td>5. HbA1c &lt;7% at Week 30 for efpeglenatide 2 mg versus placebo (Yes/No)</td>
<td></td>
</tr>
<tr>
<td>6. Change from baseline to Week 30 in FPG (mmol/L, mg/dL) for efpeglenatide 6 mg versus placebo</td>
<td></td>
</tr>
<tr>
<td>7. Change from baseline to Week 30 in FPG (mmol/L, mg/dL) for efpeglenatide 4 mg versus placebo</td>
<td></td>
</tr>
<tr>
<td>8. Change from baseline to Week 30 in body weight (kg) for efpeglenatide 2 mg versus placebo</td>
<td></td>
</tr>
<tr>
<td>The testing will stop as soon as an endpoint for an efpeglenatide dose is found to be not statistically significant at α=0.05 (2-sided). No multiplicity adjustment will be made on other secondary efficacy variables or the comparison of other efpeglenatide dose versus placebo than mentioned above.</td>
<td></td>
</tr>
<tr>
<td><strong>Exploratory endpoints</strong></td>
<td></td>
</tr>
<tr>
<td>7-point SMPG</td>
<td>Comparisons of time-to-event endpoints between treatment groups will be performed using the Cox proportional hazards regression model with the treatment groups (efpeglenatide 2, 4, or 6 mg, placebo), randomization stratum of screening HbA1c (&lt;8%, ≥8%), randomization stratum of SU use (Yes/No), and country (US, China) as the factors. The curve of the cumulative incidence of participants with rescue therapy initiation will be estimated using Kaplan-Meier method by treatment group. Summary statistics (for screening value, baseline value, observed values, and observed changes from baseline) at scheduled visits will be provided for each treatment group over the whole treatment period. The summary will include the number of observations, mean, SD, SE, minimum, median, and maximum. Graphical presentations will also be used to examine trends</td>
</tr>
<tr>
<td>Rescue therapy used during the treatment period until Week 30</td>
<td></td>
</tr>
<tr>
<td>Time to initiation of rescue therapy</td>
<td></td>
</tr>
</tbody>
</table>

(electronic 2.0)
### Endpoint Statistical Analysis Methods

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Statistical Analysis Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>over time using mean values (±SE) and mean changes from baseline (±SE) at each of the scheduled visits (using OCs).</td>
</tr>
</tbody>
</table>

ANCOVA: analysis of covariance; CI: confidence interval; FPG: fasting plasma glucose; HbA1c: hemoglobin A1c; ITT: intent-to-treat; SE: standard error; OC: observed case; SMPG: self-monitored plasma glucose; SU: sulfonylurea

#### 9.4.2 Safety analyses

All safety analyses will be performed on the safety population, as defined in Section 9.3.

The **observation period** of safety data is divided into 3 main segments as follows:

- The pretreatment period is defined as the time from informed consent up to the time of the first injection of IMP
- The on-treatment period is defined as the time from the first injection of IMP up to 30 days (7 days for hypoglycemia) after the last injection of IMP
- The posttreatment period is defined as the time starting 31 days (8 days for hypoglycemia) after the last injection of IMP (after the on-treatment period)

The AE observations will be classified per the observation periods of safety data as defined above into the following:

- Pretreatment AEs are AEs that developed or worsened or became serious during the pretreatment period
- Treatment-emergent AEs (TEAEs) are AEs that developed or worsened or became serious during the on-treatment period
- Posttreatment AEs are AEs that developed or worsened or became serious during the posttreatment period.

In addition, the on-study period is defined from the first injection of IMP up to the last study visit of the participants or the date of last available information if participants discontinue the study prematurely.
### Table 6 - Safety analyses

<table>
<thead>
<tr>
<th>Endpoints</th>
<th>Statistical Analysis Methods</th>
</tr>
</thead>
</table>
| AEs                           | All AEs will be coded to an “LLT”, “PT”, “HLT”, and “HLGT” and associated “SOC” using the version of MedDRA currently in use by the Sponsor at the time of database lock.  
  Adverse event incidence tables will be presented by primary SOC (sorted by internationally agreed order), HLGT, HLT and PT (sorted in alphabetical order) for each treatment group, showing the number (n) and percentage (%) of participants who experienced an AE.  
  The primary focus of AE reporting will be on TEAEs. Pretreatment and posttreatment AEs will be described separately.  
  Adverse event incidence table will be provided for all types of TEAEs: all TEAEs, all treatment emergent SAEs, all TEAEs leading to permanent treatment discontinuation, all TEAEs leading to death, AESI, AE requiring specific monitoring.  
  Tables will be presented on the “on-treatment period” and for the “on-study period” (for AEs, SAEs, and AEs leading to death). |
| Hypoglycemia                  | The number (%) of participants with at least 1 hypoglycemic event during the on-treatment period will be assessed per type of hypoglycemic event (see Section 8.2.5) and according to time of occurrence (nocturnal [ie, 00:00 to 05:59 am], daytime [ie, 06:00 am to 23:59]). Documented hypoglycemia (symptomatic or asymptomatic) will be also evaluated for the more stringent SMPG threshold of 3.0 mmol/L (<54 mg/dL).  
  Summaries will be presented overall and by type of event for each treatment group.  
  The total number of events (per participant-years) will be computed and summarized overall and by type of event for each treatment group. |
| Vital signs, laboratory, and ECG data | For quantitative safety parameters based on central laboratory/reading measurements, descriptive statistics will be used to summarize results and change from baseline values by visit and treatment group.  
  The incidence of potentially clinically significant abnormalities (PCSA), defined as abnormal values considered medically important by the Sponsor according to predefined criteria/thresholds based on literature review, will be summarized at any time during the on-treatment period.  
  Results will be presented both in standard international and conventional US units.  
  The incidence of normal and abnormal ECG status at any time during the on-treatment period will be summarized by treatment group whatever the baseline level and according to baseline status. |
| **Exploratory**               | Will be described in the statistical analysis plan finalized before database lock.                                                                                                                                                  |

AE: adverse event; AESI: adverse event of special interest; ECG: electrocardiogram; HLGT: higher-level grouped term; HLT: higher-level term; LLT: lower-level term; MedDRA: Medical Dictionary for Regulatory Activities; PCSA: potentially clinically significant abnormalities; PT: preferred term; SAE: serious adverse event; SMPG, self-monitored plasma glucose, SOC: system organ class; TEAE: treatment-emergent adverse event

#### 9.4.3 Other analyses

Analyses of other endpoints are detailed in Table 7.
Table 7 - Other analyses

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Statistical Analysis Methods</th>
</tr>
</thead>
</table>
| Efpeglenatide ADA                | Summaries of ADA data will be for participants treated with efpeglenatide only. All summaries related to kinetics of ADA response (ADA status and magnitude, ADA attributes, participant status, ADA incidence) will be descriptive; no statistical significance tests will be performed on ADA data:  
  - Number and percentage of participants by ADA status (positive/negative) at scheduled visits  
  - Number and percentage of participants with treatment-induced ADAs (among the participants ADA negative at baseline) during the study period  
  - Number and percentage of participants with treatment-boosted ADAs (among the participants ADA positive at baseline) during the study period  
  - ADA titer at scheduled visits  
  - Number and percentage of participants by ADA cross-reactivity to endogenous GLP-1 (positive/negative) at scheduled visits  
  - Number and percentage of participants by ADA cross-reactivity to endogenous glucagon (positive or negative) at scheduled visits  
  - Number and percentage of participants with ADAs directed against the PEG linker of efpeglenatide at scheduled visits  
  Correlation, scatterplots and/or subgroup analyses will be conducted as appropriate to assess the relationship between immunogenicity endpoints and efficacy/safety assessments. |

| PK endpoints: serum concentration of efpeglenatide at predose and post dose | Efpeglenatide predose and postdose serum concentrations of participants in the efpeglenatide groups will be listed and summarized by visit in the PK population, using descriptive statistics by n, geometric mean, coefficient of variation, median, minimum, and maximum.                                                |


9.5 INTERIM ANALYSES

Not applicable.

9.5.1 Data Monitoring Committee (DMC)

See Appendix 1 (Section 10.1) for details.
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS

10.1 APPENDIX 1: REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS

10.1.1 Regulatory and Ethical Considerations

- This study will be conducted in accordance with the protocol and with the following:
  - Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines
  - Applicable ICH Good Clinical Practice (GCP) Guidelines
  - Applicable laws and regulations

- The protocol, protocol amendments, ICF, IB, and other relevant documents (eg, advertisements) must be submitted to an IRB/IEC by the Investigator and reviewed and approved by the IRB/IEC before the study is initiated.

- Any amendments to the protocol will require IRB/IEC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.

- The Investigator will be responsible for the following:
  - Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/IEC
  - Notifying the IRB/IEC of SAEs or other significant safety findings as required by IRB/IEC procedures
  - Providing oversight of the conduct of the study at the site and adherence to requirements of 21 Code of Federal Regulations (CFR), ICH guidelines, the IRB/IEC, European Regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations

10.1.2 Informed Consent Process

- The Investigator or his/her representative will explain the nature of the study to the participant and answer all questions regarding the study.
- Participants must be informed that their participation is voluntary. Participants will be required to sign a statement of informed consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA) requirements, where applicable, and the IRB/IEC or study center.

- The medical record must include a statement that written informed consent was obtained before the participant was enrolled in the study and the date the written consent was obtained. The authorized person obtaining the informed consent must also sign the ICF.

- Participants must be reconsented to the most current version of the ICF(s) during their participation in the study.

- A copy of the ICF(s) must be provided to the participant.

- Participants who are rescreened are required to sign a new ICF.

- The ICF will contain a separate section that addresses the participation in the postdose PK assessment substudy. The Investigator or authorized designee will explain to each participant the objectives of the exploratory research. Participants will be told that they are free to refuse to participate and may withdraw their consent at any time and for any reason during the storage period. A separate signature will be required to document a participant's agreement to allow any remaining specimens to be used for exploratory research. Participants who decline to participate in this optional research will not provide this separate signature.

10.1.3 Data Protection

- Participants will be assigned a unique identifier by the Sponsor. Any participant records or datasets that are transferred to the Sponsor will contain the identifier only; participant names or any information which would make the participant identifiable will not be transferred.

- The participant must be informed that his/her personal study-related data will be used by the Sponsor in accordance with local data protection law. The level of disclosure must also be explained to the participant.

- The participant must be informed that his/her medical records may be examined by Clinical Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory authorities.

- Participants’ race and ethnicity (race: white, black or African American, Asian, Other not reported, unknown; ethnicity: Hispanic, Not Hispanic) will be collected in this study because these data are required by several regulatory authorities (eg, on African American population for US Food and Drug Administration (FDA).

- The data collected in this study will only be used for the purpose(s) of the study and to document the evaluation of the benefit/risk ratio, efficacy, and safety of the product(s). They may be further processed if they have been anonymized.
10.1.4 Committees Structure

10.1.4.1 Data Monitoring Committee

An independent DMC with members who are independent from the Sponsor and the Investigators will meet on a regular basis and will be responsible for the following:

- Review of accumulating clinical study safety data, and
- Making a recommendation to the Sponsor regarding the study following each meeting

The DMC will review and analyze, on a regular basis, unblinded safety data throughout the study, as well as safety data from the other ongoing clinical studies conducted with efpeglenatide (a single DMC for the whole efpeglenatide program). Details describing the DMC processes and procedures are outlined in the DMC Charter. To maintain continuous blinding and study integrity, the analysis will be conducted by an independent statistician who will directly transfer data to DMC members, and measures will be taken to ensure the validity of the data.

10.1.4.2 Clinical Endpoint Committee

Independent CEC(s) will be composed of experts in the field of cardiology, neurology, and gastroenterology (and other appropriate medical specialties as needed). This committee will be independent from the Sponsor, the CRO and the Investigators, and will be implemented to review, assess and/or adjudicate all events of death, selected CV events (non-fatal myocardial infarction, stroke, unstable angina leading to hospitalization, and heart failure leading to hospitalization), pancreatic events, and other selected AEs (to be defined in the CEC charter). This review will be conducted in a blinded manner with regard to study treatment.

10.1.4.3 Independent Expert

An independent ophthalmologist expert will review in a treatment-blinded manner all reported AEs suspected to be diabetic retinopathy-related to assess the presence of retinopathy and relationship of reported AE to IMP.

Investigators are reminded that all participants should have eye examinations based on their retinopathy status, performed by a professional eye care provider according to International Council of Ophthalmology (ICO) guidelines (9) or local standards. This should occur quarterly at minimum, especially for participants at high risk.

10.1.5 Dissemination of Clinical Study Data

Sanofi shares information about clinical trials and results on publicly accessible websites, based on company commitments, international and local legal and regulatory requirements, and other clinical trial disclosure commitments established by pharmaceutical industry associations. These websites include clinicaltrials.gov, European Union clinical trial register (eu.ctr), and sanofi.com, as well as some national registries.
In addition, results from clinical trials in participants are required to be submitted to peer-reviewed journals following internal company review for accuracy, fair balance and intellectual property. For those journals that request sharing of the analyzable data sets that are reported in the publication, interested researchers are directed to submit their request to clinicalstudydatarequest.com.

Individual participant data and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available, the Sponsor will continue to protect the privacy of participants in our clinical trials. Details on data sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com.

10.1.6 Data Quality Assurance

- All participant data relating to the study will be recorded on printed or eCRF unless transmitted to the Sponsor or designee electronically (eg, laboratory data). The Investigator is responsible for verifying that data entries are accurate and correct by physically or electronically signing the eCRF.

- The Investigator must maintain accurate documentation (source data) that supports the information entered in the eCRF.

- The Investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory agency inspections and provide direct access to source data documents.

- The Sponsor or designee is responsible for the data management of this study including quality checking of the data.

- Study monitors will perform ongoing source data verification to confirm that data entered into the eCRF by authorized site personnel are accurate, complete, and verifiable from source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.

- Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by the Investigator for 15 years after study completion unless local regulations or institutional policies require a longer retention period. No records may be destroyed during the retention period without the written approval of the Sponsor. No records may be transferred to another location or party without written notification to the Sponsor.

10.1.7 Source documents

- Source documents provide evidence for the existence of the participant and substantiate the integrity of the data collected. Source documents are filed at the Investigator’s site.

- Data reported on the eCRF or entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The Investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.

- Definition of what constitutes source data can be found in a separate study document.
10.1.8 Study and Site Closure

The Sponsor or designee reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of the Sponsor. Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have been collected and a study-site closure visit has been performed.

The Investigator may initiate study-site closure at any time, provided there is reasonable cause and sufficient notice is given in advance of the intended termination.

Reasons for the early closure of a study site by the Sponsor or Investigator may include but are not limited to:

- Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC or local health authorities, the Sponsor’s procedures, or GCP guidelines
- Inadequate recruitment of participants by the Investigator
- Discontinuation of further study intervention development

10.1.9 Publication Policy

- The results of this study may be published or presented at scientific meetings. If this is foreseen, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.
- The Sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating Investigator will be designated by mutual agreement.
- Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.

10.2 APPENDIX 2: CLINICAL LABORATORY TESTS

- The tests detailed in Table 8 will be performed by the central laboratory, except urine pregnancy tests and urinalysis by dipstick, which will be performed locally (at the study site).
- Protocol-specific requirements for inclusion or exclusion of participants are detailed in Section 5 of the protocol.
- Additional tests may be performed at a local laboratory at any time during the study as determined necessary by the Investigator or required by local regulations. If the local laboratory test results are used to evaluate an AE (diagnostic, follow-up, outcome), the results must be entered into the eCRF.
Table 8 - Protocol-required safety laboratory assessments

<table>
<thead>
<tr>
<th>Laboratory assessments</th>
<th>Parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hematology</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Platelet count</td>
</tr>
<tr>
<td></td>
<td>Red blood cell count</td>
</tr>
<tr>
<td></td>
<td>Hemoglobin</td>
</tr>
<tr>
<td></td>
<td>Hematocrit</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Clinical chemistry</strong></td>
<td>Creatinine</td>
</tr>
<tr>
<td></td>
<td>Sodium</td>
</tr>
<tr>
<td></td>
<td>Amylase</td>
</tr>
<tr>
<td><strong>Routine urinalysis</strong></td>
<td>pH, glucose, protein, blood/hemoglobin, ketones, leucocyte, by dipstick</td>
</tr>
<tr>
<td><strong>Lipid profile</strong></td>
<td>Triglyceride</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anti-drug antibodies</strong></td>
<td>Serum ADA</td>
</tr>
<tr>
<td><strong>Calcitonin</strong></td>
<td>Calcitonin</td>
</tr>
<tr>
<td><strong>Other Screening tests</strong></td>
<td>Follicle-stimulating hormone and estradiol (as needed in unconfirmed postmenopausal women)</td>
</tr>
<tr>
<td></td>
<td>NOTE: For women not of childbearing potential (Appendix 4, Section 10.4), follicle-stimulating hormone and estradiol levels should be tested in case the definition of postmenopausal or premenopausal cannot be satisfied, eg, no medical document of hysterectomy or cessation of menses &lt;12 months without an alternative medical cause.</td>
</tr>
<tr>
<td></td>
<td>• Serum β-HCG pregnancy test (as needed for women of childbearing potential)b</td>
</tr>
<tr>
<td></td>
<td>• C-peptide</td>
</tr>
</tbody>
</table>

NOTES:

a All study-required laboratory assessments will be performed by a central laboratory except urine pregnancy tests and urinalysis by dipstick, which will be performed locally; the results of each test must be entered into the eCRF.

b Urine pregnancy testing will be performed subsequent to Screening. If the urine test is positive, serum β-HCG should be tested for confirmation of the pregnancy.

ADE: antidrug antibody; ALT: alanine aminotransferase; AST: aspartate transaminase; β-HCG: beta-human chorionic gonadotropin; eGFR: Epidermal growth factor receptor; MDRD: Modification of Diet in Renal Disease; WBC: white blood cell; WOCBP: women of childbearing potential

Investigators must document their review of each laboratory safety report.

The HbA1c and FPG values that could unblind the study will not be reported to study sites or other blinded personnel after Visit 3 (Day 1), until the study has been unblinded. Details of the conditions in which unblinding can occur, and the procedure, are detailed in Section 6.3.2.
10.3 APPENDIX 3: ADVERSE EVENTS: DEFINITIONS AND PROCEDURES FOR RECORDING, EVALUATING, FOLLOW-UP, AND REPORTING

DEFINITION OF AE

AE definition

- An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
- NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.

Events meeting the AE definition

- Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (eg, ECG, radiological scans, vital signs measurements), including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the Investigator (ie, not related to progression of underlying disease)
- Exacerbation of a chronic or intermittent pre-existing conditions including either an increase in frequency and/or intensity of the conditions
- New conditions detected or diagnosed after study IMP administration even though it may have been present before the start of the study
- Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction
- Signs, symptoms, or the clinical sequelae of a suspected overdose of either study IMP or a concomitant medication
- "Lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as an AE or SAE. Such instances will be captured in the efficacy assessments. However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE if they fulfil the definition of an AE or SAE

Events NOT meeting the AE definition

- Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are associated with the underlying disease, unless judged by the Investigator to be more severe than expected for the participant’s conditions
- The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the participant’s conditions
- Medical or surgical procedure (eg, endoscopy, appendectomy): the conditions that leads to the procedure is the AE
Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital)

Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start of the study that do not worsen

**DEFINITION OF SAE**

If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions are met (eg, hospitalization for signs/symptoms of the disease under study, death due to progression of disease).

**An SAE is defined as any untoward medical occurrence that, at any dose:**

a) **Results in death**

b) **Is life-threatening**

The term “life-threatening” in the definition of “serious” refers to an event in which the participant was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe.

c) **Requires inpatient hospitalization or prolongation of existing hospitalization**

In general, hospitalization signifies that the participant has been detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician’s office or outpatient setting. Complications that occur during hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious criteria, the event is serious. When in doubt as to whether “hospitalization” occurred or was necessary, the AE should be considered serious.

Hospitalization for elective treatment of a pre-existing conditions that did not worsen from baseline is not considered an AE.

d) **Results in persistent disability/incapacity**

- The term disability means a substantial disruption of a person’s ability to conduct normal life functions.

- This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial disruption.

e) **Is a congenital anomaly/birth defect**
f) Other situations

- Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These events should usually be considered serious.

Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.

RECORDING AND FOLLOW-UP OF AE AND/OR SAE

AE and SAE/AESI recording

- When an AE/SAE occurs, it is the responsibility of the Investigator to review all documentation (eg, hospital progress notes, laboratory reports, and diagnostics reports) related to the event.

- The Investigator will then record all relevant AE/SAE information in the eCRF.

- It is not acceptable for the Investigator to send photocopies of the participant’s medical records to the Sponsor representative in lieu of completion of the SAE/AESI eCRF page.

- There may be instances when copies of medical records for certain cases are requested by Sponsor representative. In this case, all participant identifiers, with the exception of the participant number, will be redacted on the copies of the medical records before submission to Sponsor representative.

- The Investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.

- The Investigator will submit any initial SAE/AESI data to the Sponsor representative within 24 hours of its acknowledgement.

Assessment of intensity

The Investigator will make an assessment of intensity for each AE and SAE reported during the study and assign it to 1 of the following categories:

- Mild: An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities.

- Moderate: An event that causes sufficient discomfort and interferes with normal everyday activities.
• Severe: An event that prevents normal everyday activities. An AE that is assessed as severe should not be confused with an SAE. Severe is a category utilized for rating the intensity of an event; and both AEs and SAEs can be assessed as severe.

An event is defined as “serious” when it meets at least 1 of the predefined outcomes as described in the definition of an SAE, NOT when it is rated as severe.

**Assessment of causality**

• The Investigator is obligated to assess the relationship between study IMP and each occurrence of each AE/SAE.

• A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.

• The Investigator will use clinical judgment to determine the relationship.

• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as the temporal relationship of the event to study IMP administration will be considered and investigated.

• The Investigator will also consult the IB and/or Product Information, for marketed products, in his/her assessment.

• For each AE/SAE, the Investigator must document in the medical notes that he/she has reviewed the AE/SAE and has provided an assessment of causality.

• There may be situations in which an SAE has occurred and the Investigator has minimal information to include in the initial report to the Sponsor representative. However, **it is very important that the Investigator always make an assessment of causality for every event before the initial transmission of the SAE data to the Sponsor representative.**

• The Investigator may change his/her opinion of causality in light of follow-up information and send an SAE follow-up report with the updated causality assessment.

• The causality assessment is one of the criteria used when determining regulatory reporting requirements.

**Follow-up of AEs and SAEs**

• The Investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated or as requested by the Sponsor representative to elucidate the nature and/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals.

• If a participant dies during participation in the study or during a recognized follow-up period, the Investigator will provide the Sponsor representative with a copy of any postmortem findings including histopathology.

• New or updated information will be recorded in the originally completed eCRF.
• The Investigator will submit any updated SAE/AESI data to the Sponsor representative within 24 hours of receipt of the information.

REPORTING OF SAEs/AESI

SAE/AESI reporting to Sponsor representative via an electronic data collection tool

• The primary mechanism for reporting an SAE/AESI to the Sponsor representative will be the electronic data collection tool.

• If the electronic system is unavailable for more than 24 hours, then the site will use the paper SAE/AESI data collection tool.

• The site will enter the SAE/AESI data into the electronic system as soon as it becomes available.

• After the study is completed at a given site, the electronic data collection tool will be taken off-line to prevent the entry of new data or changes to existing data.

• If a site receives a report of a new SAE/AESI from a study participant or receives updated data on a previously reported SAE/AESI after the electronic data collection tool has been taken off-line, then the site can report this information on a paper SAE form or to the Sponsor representative by telephone.

• Contacts for SAE/AESI reporting can be found in a separate study document.

10.4 APPENDIX 4: CONTRACEPTIVE GUIDANCE AND COLLECTION OF PREGNANCY INFORMATION

DEFINITIONS:

Woman of childbearing potential (WOCBP)

A woman is considered fertile following menarche and until becoming postmenopausal unless permanently sterile (see below).

Women in the following categories are not considered WOCBP

1. Premenarchal

2. Premenopausal female with 1 of the following:
   - Documented hysterectomy
   - Documented bilateral salpingectomy
   - Documented bilateral oophorectomy

Note: Documentation can come from the site personnel’s: review of the participant’s medical records, medical examination, or medical history interview.
3. Postmenopausal female

- A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle-stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.

- Females on HRT and whose menopausal status is in doubt will be required to use one of the non-estrogen hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.

CONTRACEPTION GUIDANCE

Female participants

Female participants of childbearing potential are eligible to participate if they agree to use a highly effective method of contraception consistently and correctly as described in Table 9.

In addition WOCBP must refrain from donating ova for the duration of the study and at least 5 weeks after last dose of IMP.
### Table 9 - Highly effective contraceptive methods

**Highly effective contraceptive methods that are user dependent**

*Failure rate of <1% per year when used consistently and correctly.*

<table>
<thead>
<tr>
<th>Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Oral(^b)</td>
</tr>
<tr>
<td>- Intravaginal</td>
</tr>
<tr>
<td>- Transdermal</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Progestogen only hormonal contraception associated with inhibition of ovulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Oral(^b)</td>
</tr>
<tr>
<td>- Injectable</td>
</tr>
</tbody>
</table>

**Highly effective methods that are user independent**

<table>
<thead>
<tr>
<th>Implantable progestogen only hormonal contraception associated with inhibition of ovulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Intrauterine device (IUD)</td>
</tr>
<tr>
<td>- Intrauterine hormone-releasing system (IUS)</td>
</tr>
<tr>
<td>- Bilateral tubal occlusion</td>
</tr>
</tbody>
</table>

**Vasectomized partner**

*A vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used.*

**Sexual abstinence**

*Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.*

**NOTES:**

- Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent with local regulations regarding the use of contraceptive methods for participants participating in clinical studies.

- Pharmacokinetic drug-interaction potential of oral hormonal contraception with the study treatment is low, but still unknown. Therefore, if the oral contraceptive cannot be replaced by other highly effective method of contraception, with different route of administration, the hormonal contraception method must be supplemented with a male condom (for partner) during the treatment period and for at least 5 weeks (ie, until Follow-up Visit 15) after the last dose of IMP.
PREGNANCY TESTING:

- WOCBP should only be included after a confirmed menstrual period and a negative highly sensitive serum pregnancy test.
- Additional pregnancy testing should be performed at each on-site visit during the treatment period, at the last study visit (6 weeks ±7 days after the last dose of IMP), and as required locally.
- Pregnancy testing will be performed whenever a menstrual cycle is missed or when pregnancy is otherwise suspected.

COLLECTION OF PREGNANCY INFORMATION:

Male participants with partners who become pregnant

- The Investigator will attempt to collect pregnancy information on any male participant’s female partner who becomes pregnant while the male participant is in this study. This applies only to male participants who receive IMP.
- After obtaining the necessary signed informed consent from the pregnant female partner directly, the Investigator will record pregnancy information on the appropriate form and submit it to the Sponsor within 24 hours of learning of the partner’s pregnancy. The female partner will also be followed to determine the outcome of the pregnancy. Information on the status of the mother and child will be forwarded to the Sponsor. Generally, the follow-up will be no longer than 6 to 8 weeks following the estimated delivery date. Any termination of the pregnancy will be reported regardless of fetal status (presence or absence of anomalies) or indication for the procedure.

Female participants who become pregnant

- The Investigator will collect pregnancy information on any female participant who becomes pregnant while participating in this study. Information will be recorded on the appropriate form and submitted to the Sponsor within 24 hours of learning of a participant’s pregnancy. The participant will be followed to determine the outcome of the pregnancy. The Investigator will collect follow-up information on the participant and the neonate and the information will be forwarded to the Sponsor. Generally, follow-up will not be required for longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure.

Any pregnancy complication or elective termination of a pregnancy will be reported as an AE or SAE. A spontaneous abortion is always considered to be an SAE and will be reported as such. Any poststudy pregnancy related SAE considered reasonably related to the study intervention by the Investigator will be reported to the Sponsor as described in Section 8.3.4. While the Investigator is not obligated to actively seek this information in former study participants, he/she may learn of an SAE through spontaneous reporting.

- Any female participant who becomes pregnant while participating in the study will discontinue study IMP.
10.5 APPENDIX 5: LIVER AND OTHER SAFETY: SUGGESTED ACTIONS AND FOLLOW-UP ASSESSMENTS

10.5.1 Laboratory abnormalities

**NEUTROPENIA**

- **Neutrophils < 1500/mm$^3$ or according to ethnic group**
  - Repeat immediately a full blood count if value close to 1500/mm$^3$
  - **Neutrophils < 1500/mm$^3$ confirmed with signs of infection**
  - **Neutrophils < 1500/mm$^3$ confirmed with no signs of infection**

1. **DISCONTINUE** Investigational Medicinal Product, hospitalization should be considered
2. **PERFORM** biological investigations for infection

3. **INFORM** the local monitor
4. **INVESTIGATE** previous treatments particularly long-term, even a long time ago, exposure to toxic agents, e.g., benzene, X-rays, etc.
5. **PERFORM** and collect the following investigations (results):
   - RBC and platelet counts
   - Serology: EBV, (HIV), mumps, measles, rubella
6. **DECISION** for bone marrow aspiration: to be taken in specialized unit
7. **COLLECT/STORE** one sample following handling procedures described in PK sections (for studies with PK sampling) and freeze one serum sample (5 mL) on Day 1 (cessation of investigational medicinal product) and Day 5 (for further investigations)
8. **MONITOR** the leukocyte count 3 times per week for at least one week, then twice a month until it returns to normal

**Note:**
- The procedures described in the above flowchart are to be discussed with the patient only in case the event occurs. If applicable (according to local regulations), an additional consent (e.g., for HIV testing) will only be obtained in the case the event actually occurs.
- For individuals of African descent, the relevant value of concern is <1000/mm$^3$

Neutropenia is to be recorded as an AE only if at least 1 of the criteria listed in the general guidelines for reporting AEs in Appendix 3 (Section 10.3) is met.
Thrombocytopenia is to be recorded as an AE only if at least 1 of the criteria listed in the general guidelines for reporting AEs in Appendix 3 (Section 10.3) is met.

Thrombocytopenia

Platelets < 100,000/mm³ (rule out EDTA-induced pseudo-thrombocytopenia)

Repeat immediately the count (rule out EDTA anticoagulant in the sample)

Platelets < 100,000/mm³ confirmed with bleeding

1. DISCONTINUE Investigational Medicinal Product
2. HOSPITALIZATION should be considered

Platelets < 100,000/mm³ confirmed with no bleeding

1. DISCONTINUE Investigational Medicinal Product
2. INVESTIGATE for bleeding

In both situations

3. INFORM the local Monitor
4. QUESTION about last intake of quinine (drinks), alcoholism, heparin administration
5. PERFORM or collect the following investigations:
   • Complete blood count, schizocytes, creatinine
   • Bleeding time and coagulation test (fibrinogen, INR or PT, aPTT), Fibrin Degradation Product
   • Viral serology: EBV, HIV, mumps, measles, rubella
6. COLLECT/STORE one sample following handling procedures described in PK sections (for studies with PK sampling) and freeze one serum sample (5 mL) on Day 1 (cessation of investigational medicinal product) and Day 5 (for further investigations)
7. DECISION for bone marrow aspiration: to be taken in specialized unit
   • On Day 1 in the case of associated anemia and/or leukopenia
   • On Day 8 if platelets remain < 50,000/mm³
8. MONITOR the platelet count every day for at least one week and then regularly until it returns to normal

Note:
The procedures above flowchart are to be discussed with the patient only in case described in the event occurs. If applicable (according to local regulations), an additional consent (e.g., for HIV testing) will only be obtained in the case the event actually occurs.
If unable to retest in 72 hours, use original lab results to decide on further reporting/monitoring/discontinuation.

Note:
- "Baseline" refers to ALT sampled at baseline visit; or if baseline value unavailable, to the latest ALT sampled before the baseline visit. The algorithm does not apply to the instances of increase in ALT during screening.
- See Section 10.3 for guidance on safety reporting.
- Normalization is defined as ≤ULN or baseline value, if baseline value is >ULN.
INCREASE IN SERUM CREATININE

Rapid increase in serum creatinine over 150 µmol/L or rapid decrease in creatinine clearance below 50 mL/mn

Can be rapidly reversed:
• By volume repletion
• Or relief of urinary tract obstruction (according to etiology)

Cannot be rapidly reversed:
• Occurrence/aggravation of life threatening symptoms of ARF: anemia, hyperkalemia, hyperuricemia, metabolic acidosis, cardiac insufficiency, pulmonary edema, arrhythmia, DIC, etc.
• And/or predominant elimination of investigational medicinal product by renal route

1. INFORM the local monitor
2. DISCONTINUE investigational medicinal product administration
3. HOSPITALIZATION should be considered and seek for nephrologic advice
4. PERFORM the following examinations:
   • BP, HR, hydration status, ECG
   • Blood count
   • Liver function tests + CPK
   • Biochemistry, including urea
   • Urinalysis
5. COLLECT/STORE one sample following handling procedures described in PK sections (for studies with PK sampling) and freeze one serum sample (5 mL) on Day 1 (cessation of investigational medicinal product)
6. MONITOR renal function until return to baseline level (every day at the beginning, then every week)

Increase in serum creatinine is to be recorded as an AE only if at least 1 of the criteria listed in the general guidelines for reporting AEs in Appendix 3 (Section 10.3) is met.
INCREASE IN CPK SUSPECTED TO BE OF NON-CARDIAC ORIGIN AND NOT RELATED TO INTENSIVE PHYSICAL ACTIVITY

Muscular symptoms (myalgia, pain, weakness, dark urines)  Systematic CPK assessment as per protocol

Perform CPK

If Increase in CPK (expressed in ULN)

> 3 ULN

Repeat immediately the count.
If confirmed, inform the local monitor and

INVESTIGATE for the origin:
- **PERFORM**:
  - ECG
  - CPK-MB -MM
  - Troponin
  - Creatinine
  - Iono (k+, Ca²+)
  - Transaminases + Total and conjugated bilirubin
  - Myoglobin (serum and urines)
- **COLLECT/STORE** one sample following handling procedures described in PK sections (for studies with PK sampling) and freeze one serum sample (5 mL) on Day 1 (cessation of investigational medicinal product).
- **INTERVIEW** the patient about a recent intensive muscular effort, trauma, convulsions, electrical injury, injury or stress to the skeletal muscle, multiple intramuscular injections, recent surgery, concomitant medications, consumption of alcohol, morphine, cocaine.
- **SEARCH** for alternative causes to cardiac or muscular toxicity, ie, stroke, pulmonary infarction, dermatomyositis or polymyositis, convulsions, hypothyroidism, delirium tremens, muscular dystrophies.

If either the cardiac origin or the rhabdomyolysis is confirmed or if CPK > 10 ULN:
1. **DISCONTINUE** investigational medicinal product administration
2. **MONITOR** CPK every 3 days for the first week then once weekly until return to normal or for at least 3 months
3. **HOSPITALIZATION** should be considered

If the cardiac origin or the rhabdomyolysis is ruled out and if CPK ≤ 10 ULN:
**MONITOR** CPK every 3 days for the first week then once weekly until return to normal or for at least 3 months

Increase in creatine phosphokinase is to be recorded as an AE only if at least 1 of the criteria in the general guidelines for reporting AEs in Appendix 3 (Section 10.3) is met.
10.5.2 Monitoring of participants with increased lipase and/or amylase >2 ULN

GLP-1 RAs stimulate pancreatic beta-cell and suppress alpha-cell function. Some cases of acute pancreatitis have been reported with marketed GLP-1 RAs. Therefore, participants enrolled in this study should be closely monitored for any suspected pancreatitis, eg, with symptoms and/or signs of acute abdominal distress or abnormal levels of pancreatic enzymes. Serum amylase and lipase concentrations are monitored routinely at screening, baseline and periodically during the study treatment period.

In the presence of clinical signs and/or symptoms evocative of pancreatitis, eg, persistent abdominal pain, which can radiate to the back, often with characteristic positional features, with possible occurrence of nausea, vomiting, fever, and leucocytosis, further measurement of amylase and lipase should be performed. The clinical signs and/or symptoms should be documented in the source data documentation.

10.5.2.1 Elevation of amylase and/or lipase >2 × ULN without clinical signs and/or symptoms

In any case where amylase and/or lipase are >2 × ULN, a retest (centrally assessed as far as possible) must be performed as follows:

- If value(s) is/are >2 to 3 × ULN: retest within 7 days
- If value(s) is/are >3 × ULN: retest within 48 hours
- If the value(s) remain(s) >2 × ULN upon retesting: amylase and/or lipase levels should be retested weekly until values are <2 × ULN

In case a retest is >2 × ULN, a gastroenterological evaluation and imaging (ultrasound and/or computed tomography [CT] or magnetic resonance imaging [MRI] with contrast, as appropriate) is highly recommended. The absence of clinical signs and/or symptoms should be documented in the source documents (if clinical signs and/or symptoms develop, please see Section 10.5.2.2).

Best clinical judgment is to be used when interpreting elevated serum amylase and lipase levels in asymptomatic participants. Temporary discontinuation of the IMP may be considered in these cases if deemed necessary by the Investigator.

10.5.2.2 Elevation of amylase and/or lipase >2 × ULN with clinical signs and/or symptoms

In the presence of clinical signs and/or symptoms evocative of pancreatitis (as previously described) associated with elevated amylase and/or lipase, treatment with the IMP should be promptly and at least temporarily discontinued pending further clinical evaluation and diagnosis confirmation. Clinical signs and/or symptoms are to be documented in the source data. A laboratory determination of amylase and lipase must be obtained at the time of the event and again within 48 hours or earlier as clinically indicated. If the value(s) remain(s) >2 × ULN, then amylase and/or lipase levels should be retested as described in Section 10.5.2.1, or more often if clinically indicated.
A gastroenterologic evaluation and imaging (ultrasound and/or CT or MRI with contrast, as appropriate) must be performed as clinically indicated and as per clinical practice and local guidelines. If a diagnosis of pancreatitis is confirmed, IMP should not be restarted and should be permanently discontinued.

In both cases as previously described (Section 10.5.2.1 and Section 10.5.2.2), all laboratory or clinical documentations must be collected. If the retest confirms lipase and/or amylase values are >2 ULN, the event must be reported in the eCRF on the specific AE form and the specific complementary forms, using the appropriate verbatim, eg, “increased amylase and/or lipase” in case of isolated enzyme elevation, “suspected pancreatitis” in the presence of clinical signs evocative of pancreatitis if the diagnosis is suspected but cannot be confirmed or excluded, and “pancreatitis” if the diagnosis has been confirmed.

10.5.3 Management of participants with increased calcitonin values

During the course of the study, if calcitonin value is found ≥20 pg/mL (5.9 pmol/L):

- A retest should be performed by the central laboratory within 7 days
- The following are to be collected and recorded as soon as possible:
  - Conditions other than C-cell disease which may increase calcitonin levels, such as: smoking status, treatment with proton-pump inhibitor (eg, omeprazole), autoimmune thyroid diseases (Hashimoto’s thyroiditis or Grave’s disease), differentiated thyroid cancer, hypercalcemia, hypergastrinemia, chronic renal insufficiency (not on dialysis), other neuro-endocrine tumors (lung small cell carcinoma, intestinal carcinoid), acute pulmonary inflammatory conditions, or sepsis
  - Personal and/or familial medical history in relation with thyroid or other endocrine diseases
  - Specific physical examination (neck, thyroid gland)

If the retest confirms that calcitonin value is ≥20 pg/mL:

- The event must be reported in the eCRF on the AE form (as final diagnostic if available or as increased calcitonin); all appropriate clinical and laboratory documentations should also be reported in the corresponding eCRF pages.
- An ultrasound scan of the thyroid is highly recommended to be performed and the participant may be referred to a specialist if judged necessary (per clinical practice and local guidelines).
- The participant should continue to be followed according to protocol schedule (including planned calcitonin measurements). The AE form and all other related eCRF pages should be updated with any new information collected during the follow-up.
• If calcitonin value ≥50 pg/mL (14.75 pmol/L) is found at any time during follow-up, the participant should be permanently discontinued from IMP and referred to a specialist. As far as possible, blood should be collected 1 to 2 weeks after IMP discontinuation and sent to the central laboratory for calcitonin measurement. As per protocol, the participant should be followed according to study procedures up to the scheduled end of the study.

If at any time during follow-up calcitonin value ≥20 pg/mL increases by 20% or more between 2 assessments (while remaining below 50 pg/mL), a repeated measurement should be performed earlier than scheduled in the protocol, ie, 1 month later. Once results are available, discussion with Sponsor representative should be initiated without delay for further guidance.

10.5.4 Gastrointestinal events in relation to acute renal failure

Acute renal impairment caused by dehydration is a potential risk described for other GLP-1 RAs. Acute renal impairment is not thought to be caused directly by GLP-1 RAs (including efpeglenatide) without dehydration.

In case of prolonged or severe nausea and vomiting, if clinically indicated, serum creatinine measurement should be performed at the central laboratory. If there is an acute increase of serum creatinine, metformin must be discontinued (if concomitantly taken) until resolution of renal dysfunction. Please also refer to Appendix 5 (Section 10.5), Increase in serum creatinine flowchart for further recommendations.

10.6 APPENDIX 6: MEDICAL DEVICE INCIDENTS: DEFINITION AND PROCEDURES FOR RECORDING, EVALUATING, FOLLOW-UP, AND REPORTING

Not applicable.

10.7 APPENDIX 7: COUNTRY-SPECIFIC REQUIREMENTS

Not applicable.
10.8 APPENDIX 8: HYPOGLYCEMIA CLASSIFICATION

Figure 2 - Hypoglycemia classification

*The patient is not able to treat her/himself because of the acute neurological impairment and requires another person to actively administer sugar, glucagon or intravenous glucose.
# 10.9 APPENDIX 9: ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>AESI</td>
<td>adverse event of special interest</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine aminotransferase</td>
</tr>
<tr>
<td>ANCOVA</td>
<td>analysis of covariance</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate aminotransferase</td>
</tr>
<tr>
<td>BP</td>
<td>blood pressure</td>
</tr>
<tr>
<td>CEC</td>
<td>Clinical Endpoint Committee</td>
</tr>
<tr>
<td>CFR</td>
<td>Code of Federal Regulations</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>CV</td>
<td>cardiovascular</td>
</tr>
<tr>
<td>DMC</td>
<td>data monitoring committee</td>
</tr>
<tr>
<td>DPP-4</td>
<td>dipeptidyl peptidase 4</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>eCRF</td>
<td>electronic Case Report Form</td>
</tr>
<tr>
<td>eGFR</td>
<td>estimated glomerular filtration rate</td>
</tr>
<tr>
<td>EOT</td>
<td>end of treatment</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>FPG</td>
<td>fasting plasma glucose</td>
</tr>
<tr>
<td>FSH</td>
<td>follicle-stimulating hormone</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>GI</td>
<td>gastrointestinal</td>
</tr>
<tr>
<td>GLP-1</td>
<td>glucagon-like peptide-1</td>
</tr>
<tr>
<td>GLP-1 RA</td>
<td>glucagon-like peptide 1 receptor agonist</td>
</tr>
<tr>
<td>HbA1c</td>
<td>hemoglobin A1c</td>
</tr>
<tr>
<td>HRT</td>
<td>hormonal replacement therapy</td>
</tr>
<tr>
<td>IB</td>
<td>Investigator's Brochure</td>
</tr>
<tr>
<td>ICF</td>
<td>informed consent form</td>
</tr>
<tr>
<td>ICO</td>
<td>International Council of Ophthalmology</td>
</tr>
<tr>
<td>IEC</td>
<td>Independent Ethics Committees</td>
</tr>
<tr>
<td>IMP</td>
<td>investigational medicinal product</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Boards</td>
</tr>
<tr>
<td>IRT</td>
<td>interactive response technology</td>
</tr>
<tr>
<td>ITT</td>
<td>intent-to-treat</td>
</tr>
<tr>
<td>MDRD</td>
<td>modification of diet in renal disease</td>
</tr>
<tr>
<td>MEN 2</td>
<td>multiple endocrine neoplasia syndrome type 2</td>
</tr>
<tr>
<td>MI</td>
<td>multiple imputation</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>MTC</td>
<td>medullary thyroid cancer</td>
</tr>
<tr>
<td>NIMP</td>
<td>noninvestigational medicinal product</td>
</tr>
<tr>
<td>OAD</td>
<td>oral antidiabetic</td>
</tr>
<tr>
<td>OC</td>
<td>observed cases</td>
</tr>
</tbody>
</table>
PEG: polyethylene glycol
PFS: prefilled syringe
PK: pharmacokinetic
popPK: population PK
PPG: postprandial plasma glucose
SAE: serious adverse event
SC: subcutaneous
SD: standard deviation
SE: standard error
SGLT2: sodium/glucose cotransporter 2
SMPG: self-monitored plasma glucose
SoA: schedule of activities
SU: sulfonylurea
SUSAR: suspected unexpected serious adverse reaction
T2DM: type-2 diabetes mellitus
TEAEs: treatment-emergent adverse events
ULN: upper limit of normal
WOCBP: women of childbearing potential
11 REFERENCES


## ELECTRONIC SIGNATURES

<table>
<thead>
<tr>
<th>Signed by</th>
<th>Meaning of Signature</th>
<th>Server Date (dd-MMM-yyyy HH:mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Clinical Approval</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Regulatory Approval</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinical Approval</td>
<td></td>
</tr>
</tbody>
</table>